

NOVEL CALCIUM-BINDING PROTEINS

BACKGROUND OF INVENTION

5 1. Field of the Invention

The present invention relates to novel calcium-binding proteins, DNA encoding them, antibodies against the calcium-binding proteins, hybridomas producing the antibodies, diagnostic agents comprising the antibodies, etc.

10 2. Related Art

Extracellular calcium ion concentration is known to play a role in the regulation of cellular proliferation and differentiation. On the other hand, intracellular calcium ion is one of the key transfer factors for intracellular signal transduction. The calcium signals are transduced by various calcium-binding proteins (CaBP). Calcium-binding proteins are largely classified as those with the EF-hand motif, such as calmodulin, troponin C, the S100 protein family, etc. and those without EF-hands, such as the annexin family. These are presumed to carry out separate and important physiological roles, but their physiological roles have not been completely elucidated.

25 Calmodulin mediates many calcium ion-dependent cellular reactions, and it is understood to be a ubiquitous CaBP required during mitosis. In contrast, CaBPs of the S100 protein family are expressed specifically according to cell cycle or cell type, and they are implicated in specific signal transduction for cellular division and differentiation. The S100 protein family includes S100 $\alpha$ , S100 $\beta$ , calyculin, MRP8, MRP14, etc., each of which have 2 EF-hand motifs.

35 Thus, the study of the presence and function of CaBPs is crucial for understanding the mechanisms of cell proliferation and differentiation, and is expected to yield useful knowledge for the understanding, diagnosis

100220" 3020760

## SUMMARY OF INVENTION

The present inventors have searched for calcium-binding proteins from among various specimens, and have found that a protein with considerable calcium-binding activity is present in bovine amniotic fluid. In addition, the inventors have isolated the calcium-binding protein to obtain a substantially pure protein, and have determined its full amino acid sequence and the sequence of the DNA encoding it. This calcium-binding protein is a hitherto-unknown novel protein belonging to the S100 protein family and present in extracellular fluid, and it has been named CAAF1 (Calcium binding protein in Amniotic Fluid 1).

Furthermore, the present inventors have prepared antibodies against CAAF1, have studied the presence of the proteins in various tissues, and have also constructed a system for a quantitative assay thereof and have found their usefulness as diagnostic agents for a number of diseases.

The present invention further provides DNAs encoding the above-mentioned proteins, expression vectors

including the DNA, and host cells transformed with the expression vectors.

The present invention still further provides a method for producing the calcium-binding proteins by  
5 extraction from bovine amniotic fluid or tissue, human tissue, or by using the above-mentioned host cells.

The present invention still further provides antibodies against the calcium-binding proteins,  
10 hybridomas which produce the antibodies, and methods of producing the antibodies.

The present invention still further provides diagnostic agents comprising the antibodies and analysis methods employing them.

#### BRIEF EXPLANATION OF THE DRAWINGS

15 Fig. 1 shows the amino acid sequence of bovine calcium-binding protein and the DNA sequence encoding it. In Fig. 1, the lines labelled as N indicate the results of determining the N-terminal amino acid sequence of the protein, and the dotted lines labelled as V8-P indicate  
20 the amino acid sequence of the two peptide fragments produced when the protein was cut with *S. aureus* V8 proteinase.

Fig. 2 shows the amino acid sequence of bovine calcium-binding protein and the DNA sequence encoding it.  
25 In Fig. 2, the lines labelled as N indicate the results of determining the N-terminal amino acid sequence of the protein, the dotted lines labelled as V8-P indicate the amino acid sequence of the two peptide fragments produced when the protein was cut with *S. aureus* V8 proteinase,  
30 and broken lines labelled as Lysyl-P indicate the amino acid sequence of fragments produced when the protein was cut with lysylendopeptidase.

Fig. 3 shows electrophoretic patterns of bovine amniotic fluid with a Tricine-SDS-PAGE silver staining  
35 gel (A) and  $^{45}\text{Ca}^{2+}$  overlay autoradiogram after Tricine-SDS-PAGE (B). In Fig. 3, lane 1 represents

electrophoresis in the presence of mercaptoethanol and lane 2 in the absence thereof.

Fig. 4 shows electrophoretic patterns of bovine amniotic fluid with cationic exchange chromatography (A), each of the fractions thereof in a Tricine-SDS-PAGE silver staining gel (B) and with  $^{45}\text{Ca}^{2+}$  overlay autoradiography after Tricine-SDS-PAGE (C). In Fig. 4, CAAF1 is contained in the portions denoted by \*1.

Fig. 5 shows an electrophoretic pattern of purified bovine CAAF1 in an SDS-PAGE-analyzed silver stained gel.

Fig. 6 is a graph showing the apparent molecular weight of bovine CAAF1 by gel filtration chromatography.

Fig. 7 is a graph showing an example of the relationship between the calcium-binding protein concentration and absorbance (calibration curve) when the calcium-binding protein is assayed using biotin-labelled anti-calcium-binding protein antibody.

Fig. 8 is a photograph which shows the results of immunohistological staining and morphology of tissue slice of fetal calf skin (cuticle) using CAAF1-22-5 monoclonal antibody.

Fig. 9 is a photograph which shows the results of immunohistological staining and morphology of tissue slice of fetal calf espagus (mucosa) using CAAF1-22-5 monoclonal antibody.

Fig. 10 is a photograph which shows the results of immunohistological staining and morphology of tissue slice of fetal calf amniotic membrane using CAAF1-22-5 monoclonal antibody.

Fig. 11 is a photograph which shows the results of immunohistological staining and morphology of tissue slice of fetal calf thymus using CAAF1-22-5 monoclonal antibody.

Fig. 12 is a photograph which shows the results of immunohistological staining and morphology of tissue slice of adult human esophagus (normal membrane) using

CAAF1-22-5 monoclonal antibody.

Fig. 13 is a photograph which shows the results of immunohistological staining and morphology of tissue slice of adult human esophagus (cancer cells and infiltrated cells) using CAAF1-22-5 monoclonal antibody.

#### DETAILED DESCRIPTION OF THE INVENTION

The calcium-binding protein of the present invention comprises any amino acid sequence which is substantially identical to the amino acid sequence listed in SEQ ID NO: 1 or 12. By "substantially identical" is meant that it is either exactly identical or is modified at one or a few amino acids while retaining the calcium-binding activity. "Modified" as used here refers to a change in the amino acid sequence listed in SEQ ID NO: 1 or 12 by a deletion, addition or amino acid substitution, or a combination thereof.

Furthermore, "a few" means less than, for example, about 10% of the entire number of amino acids of the amino acid sequence listed in SEQ ID NO: <sup>19</sup>1 or <sup>20</sup>12, such as 10 or fewer, and preferable 5 or fewer. Thus, according to the present invention, any amino acid sequence which is substantially identical to the amino acid sequence listed in SEQ ID NO: <sup>19</sup>1 or <sup>20</sup>12 encompasses amino acid sequences with an addition, deletion or substitution of 1 to 10, and preferably 1 to 5 amino acids which still have calcium-binding activity.

The present invention also includes fragments of the calcium-binding proteins having the various amino acid sequences described above. Such fragments are useful as immunogens for producing antibodies against the calcium-binding protein, regardless of whether or not they have calcium-binding activity.

The present invention also encompasses fused proteins of the above-mentioned calcium-binding protein or fragments thereof and other protein. The partner protein composing the fused protein may be any desired protein including glutathione-S-transferase, superoxide

dismutase, lacZ or the like. Such fused proteins are useful for efficient expression of the calcium-binding protein of the present invention or fragments thereof by recombinant methods.

5           The present invention also relates to derivatives of the above-mentioned calcium-binding proteins and fragments thereof.

Derivatives of the calcium-binding protein within the scope of the present specification include  
10 glycosylated variants and covalent and aggregated conjugates with other chemical components. Covalent derivatives may be prepared by bonding with a functional group on an amino acid side chain or the N- or C-terminal of the calcium-binding protein, by a method well-known to  
15 those skilled in the art. Such derivatives include fatty esters and amides of carboxyl terminal or carboxyl group-containing residues, O-acyl derivatives of residues containing a hydroxyl group, and N-acyl derivatives of  
20 amino terminal or amino group-containing residues such as lysine or arginine, but are not limited to these. The alkyl component of the acyl group may be selected from, for example straight chain alkyl groups of C<sub>3</sub>-C<sub>18</sub> to form alkanoyl aroyls.

The major derivatives are covalent conjugates of  
25 other proteins with a calcium-binding protein such as CAAF1 or fragments thereof. These derivatives are obtained either by recombinant culturing or by synthesis using substances known by those skilled in the art to be useful for N- or C-terminal fusion or for crosslinking of  
30 proteins through reactive side groups. Preferred reaction sites between a crosslinking agent and a calcium-binding protein such as CAAF1 are free amino groups, free carboxyl groups, carbohydrates and cysteine residues.

35           The present invention also relates to uses of the derivative resulting from covalent or aggregate

association with a chemical component. The calcium-binding protein of the present invention may also be radioiodinated by, for example, the chloramine T method, or conjugated to a fluorescent component such as a rare earth metal chelate or other types of detectable group, to be labelled for use in, for example, an assay system for the calcium-binding protein.

The present invention further provides a method for producing the above-mentioned calcium-binding protein, fragments thereof, or fused proteins thereof.

The calcium-binding protein having the amino acid sequence listed as Sequence No. 1 or 12 may be isolated or purified from, for example, bovine amniotic fluid or other tissue, or human tissues. The isolation or purification may be performed by combining any of a variety of known purification methods, to the required degree of purity. Methods of purification which may be used include cationic exchange, anionic exchange, gel filtration, hydrophobic, isoelectric, immunologic affinity, chelate affinity, reverse phase and other kinds of chromatography, as well as fractional precipitation, etc. Other methods may also be used.

After obtaining the calcium-binding protein in sufficient purity and amount, its amino acid sequence from the N-terminal may be determined using a protein sequencer. The amino acid sequence outside the vicinity of the N-terminal may be determined, for example, by first decomposing the calcium-binding protein with a suitable protease or the like, purifying the fragment peptides obtained by the decomposition using a purification method such as reverse phase chromatography, determining the amino acid sequence from the N-terminals in the same manner, and then combining the sequences to determine the entire amino acid sequence.

The entire amino acid sequence may be determined in this manner, but such a method is not always necessary. For example, the general method described below may be

used to clone DNA encoding the calcium-binding protein from part of the amino acid sequence, determine its nucleotide sequence, and deduce the amino acid sequence of the calcium-binding protein from the cDNA sequence.

5       The calcium-binding proteins of the present invention and fragments thereof may also be chemically synthesized by conventional methods. Such methods include those described in Janis D. Young, Solid Phase Peptide Synthesis, (Pierce Chemical Co., Rockford, IL, 10       1984); M. Bondanszky and A. Bondanszky, The Practice of Peptide Synthesis, (Springer-Verlag, New York, 1984); and M. Bondanszky, The Principles of Peptide Synthesis, (Springer-Verlag, New York, 1984).

15       These are all included in the present specification as reference. For example, the azide method, acid chloride method, acid anhydride method, mixed acid anhydride method, active ester (e.g. p-nitrophenyl ester, N-hydroxy succinimide ester or cyanomethyl ester) method, carbodiimidazole method, oxidation-reduction method or 20       DCC/additive method may be used. Both solid phase and liquid phase synthesis may be applied in the aforementioned methods.

25       The calcium-binding proteins of the present invention may be appropriately prepared according to the methods mentioned above which are typically used for peptide synthesis, and this usually involves the so-called step technique involving condensation of amino acids in order one-by-one onto the terminal amino acid, or coupling of peptide fragments onto the terminal amino 30       acid. In order to avoid coupling at wrong sites, the amino groups not used in the coupling reaction must be protected.

35       When solid phase synthesis is employed, the C-terminal amino acid is bound to an insoluble carrier or support through its carboxyl group. The insoluble carrier is not particularly restricted so long as it is attachable to the reactive carboxyl group. Examples of



insoluble carriers of this type include halomethyl resins, such as chloromethyl and bromomethyl resins, hydroxymethyl resins, phenol resins, tert-alkyloxycarbonyl hydrazide resins, and the like.

5       The amino acids whose amino groups have been protected are successively linked by condensation between their activated carboxyl groups and the reactive amino group of the already formed peptide chain, for a stepwise synthesis of the peptide. Once the complete sequence has  
10       been synthesized, the peptide is cut off from the insoluble carrier to obtain the peptide. This solid phase approach is described in general terms by Merrifield, et al. in J. Am. Chem. Soc., 85: 2149 - 2156 (1963). This explanation is incorporated into the  
15       present specification for reference.

      A common means of peptide separation, for example extraction, precipitation, electrophoresis or a chromatography technique, may be used to isolate and purify the prepared calcium-binding protein or fragments  
20       thereof from the reaction mixture.

      The calcium-binding protein of the present invention or fragments or fused proteins thereof may also be produced by a genetic engineering method. In such methods, host cells transformed by an expression vector  
25       comprising DNA encoding the desired protein or polypeptide are cultured and the protein or polypeptide of interest is collected from the culture. The host cells for this purpose may be either prokaryotic or eukaryotic cells. The prokaryotic cells may be, for  
30       example, bacteria which may be either gram-positive or gram-negative bacteria.

      An example of a gram-negative bacterium is *Escherichia coli*, and examples of gram-positive bacteria are *Bacillus subtilis*, *Bacillus liqueformis*, etc., and  
35       commonly used hosts may be used appropriately. Other prokaryotic host cells which may be used include microorganisms of the genus *Actinomyces* and the genus

*Streptomyces*.

The eukaryotic host may be either a lower eukaryotic host or higher eukaryotic host. Examples of lower eukaryotic hosts include gemella, fungi, etc. Preferred  
5 fungi are unicellular fungi such as yeast, or filamentous fungi. The yeast may be yeast of the genus *Saccharomyces*, such as *Saccharomyces cerevisiae*, and the filamentous fungi may be filamentous fungi of the genus *Aspergillus*, such as *Aspergillus niger* and *Aspergillus*  
10 *orizae*, as well as filamentous fungi of the genus *Penicillus*.

The higher eukaryotic organism host may be either an animal or plant. Animal hosts include insects and their cultured cells, mammals and their cultured cells, etc.  
15 Typical insects used are silk worm and cultured cells thereof, and mammals used are mice, rats, hamsters, cows, pigs, etc. and cultured cells thereof, as well as cultured human cells. Specific examples of animal cells include Chinese hamster ovary cells (CHO), HeLa cells,  
20 baby rat kidney cells (BRK), simian cells (COS), etc.

When the host used is cells they are cultured, and when the host is an animal or plant it is raised or cultivated. The culturing, raising or cultivation may be conducted according to well-established conventional  
25 methods. A common method used for protein purification may be used to purify the protein of the present invention from cultures, and any of the purification methods, for example listed earlier for purification from, bovine amniotic fluid, may be appropriately  
30 combined.

The calcium-binding protein of the present invention or fragments thereof may be obtained at various degrees of purity, depending on the desired use. The purification may be achieved using the protein-refining  
35 technique disclosed in this specification, or by immunologic affinity chromatography with an antibody described in this specification. A summary of

immunologic affinity chromatography is given in the present specification.

5 The present invention provides a gene, typically DNA, encoding the protein of the present invention, for production of the protein. This DNA typically has the nucleotide sequence listed in SEQ ID NO: 1 or 12, but it is not limited thereto, and DNA having various nucleotide sequences with degeneration of the codons coding for the amino acid sequence listed in SEQ ID NO: 1 or 12 are also included in the present invention. Furthermore, the above description implies that DNA encoding proteins which comprise amino acid sequences which are substantially identical to the amino acid sequence listed in SEQ ID NO: 1 or 12 are also included in the present invention. DNA encoding protein fragments or fused proteins of the above-mentioned protein is also included in the present invention.

10 The present invention also encompasses DNA which is sufficiently homologous with the different DNA described above so as to allow it to hybridize therewith, and which encodes a protein with calcium-binding activity. Factors influencing hybridization (or reassociation by which double strands of complementary DNA strands are formed) include temperature, salt concentration, base pair matching errors, length of DNA fragments, diversity, etc. The stability of associated double stranded nucleic acids is expressed in terms of melting temperature ( $T_m$ , temperature at which 50% melting occurs), and when the probe DNA is at least 150 base pairs long, hybridization is usually performed at the  $T_m - 25^\circ\text{C}$  at which the highest hybridization rate may be achieved.

20 The  $T_m$  is affected by the homology between the nucleotide sequences of the probe and the DNA, but hybridization is commonly performed at a temperature of 68°C, or 42°C in the presence of 50% formaldehyde. The conditions employed for such hybridization are, for example, 6X SSC, 50% formaldehyde, 5X Denhardt solution,

20 mM Tris-HCl, 0.5% SDS, 100 µg/ml denatured salmon sperm DNA, in pH 7.5 solution, 42°C, 24 hours. The degree of homology is preferably above 60%, and more preferably above 70%.

5           To obtain the DNA, typically, a cDNA library prepared from bovine or human tissue, such as fetal calf esophagus, human neutrophil, is screened using a probe designed from a partial amino acid sequence of the bovine or human calcium-binding protein of interest. The DNA  
10       obtained in this manner will have, for example, the nucleotide sequence listed in SEQ ID NO: 1 or 12. In this case, the amino acid sequence obtained from the purified calcium-binding protein may be used according to known techniques to isolate DNA encoding the calcium-  
15       binding protein and determine its nucleotide sequence.

          For example, an amino acid sequence obtained from the calcium-binding protein may be used to devise a PCR primer and synthesize a DNA probe by RT-PCR, and then the DNA probe may be used to isolate the cDNA of the calcium-  
20       binding protein. A number of standard methods are either described or referred to in Maniatis, et al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor NY) or F.M. Ausubel, et al., Biology (Greene Publishing Associates, Brooklyn,  
25       NY).

          Once the cDNA has been isolated, its nucleotide sequence may be determined by known techniques. From this nucleotide sequence, the amino acid sequence of CAAF1 which is the primary translation product, i.e. the  
30       amino acid sequence before possible posttranslational modification, may be deduced.

          DNA encoding amino acid sequences which are not identical to but are substantially identical to the amino acid sequence listed in SEQ ID NO: 1 or 12, such as  
35       amino acid sequences modified by one or a few amino acid additions, deletions or substitutions, may be prepared, for example, using DNA with the nucleotide sequence

listed in SEQ ID NO: 1 or 12 as a template, and inducing a site-specific mutation with a mutagenic primer.

The mutation site may be decided in advance, but that is not an essential condition. For example, in order to optimize the property of a mutant at a specific residue site, a random mutation may be induced at a target codon, and the subsequently expressed CAAF1 mutants screened for the desired property. There are methods publicly known to those skilled in the art for creating substitution mutations at predetermined sites of DNA with known sequences, and one of these is M13 primer mutation induction.

DNA encoding fragments of the above-mentioned protein may be prepared by cutting DNA encoding the protein longer than the fragment of interest with restriction endonuclease, or by shortening the DNA to a desired length with exonuclease, or by introducing a translation initiation codon or translation termination codon into DNA encoding the protein longer than the fragment of interest.

Alternatively, the DNA of the present invention may be chemically synthesized by common methods, for example solid phase synthesis, such as the phosphoamide method, etc.

DNA encoding a fused protein may be created by linking DNA encoding the calcium-binding protein of the present invention or a fragment thereof, with DNA encoding the partner protein which is to compose the fused protein.

For the purpose of the present invention, when the DNA sequences are functionally interrelated, they are functionally linked. For example, if the polypeptide is to be expressed as a precursor protein or is connected with localization of the polypeptide in the membrane or secretion of the polypeptide, the precursor sequence or secretion leader DNA is functionally linked to that of the polypeptide. To regulate transcription of the

polypeptide, a promoter is functionally linked to the coding sequence. When the coding sequence is to be placed to allow translation, the ribosome-binding site is functionally linked to the coding sequence. In general,  
5 "functionally linked" means linked and within the reading frame. However, genetic factors such as a repressor genes are not adjacently linked but are linked to the operator sequence which regulates expression.

The present invention provides vectors which express  
10 DNA encoding the calcium-binding protein or a fragment thereof.

Expression vectors are usually selfreplicating DNA or RNA frames containing a gene of interest functionally linked to an appropriate gene regulating factor which is  
15 recognized in appropriate host cells. Such regulating factors are capable of acting on expression in appropriate hosts. The specific type of regulating factor required for expression depends on the final host cells used.

Gene regulating factors are generally prokaryotic promoter systems and eukaryotic promoter expression  
20 regulating systems, and they may be transcription promoters, any desired operator which regulates initiation of transcription, transcription enhancers which raise the level of mRNA expression, sequences  
25 coding for appropriate ribosome binding sites, and sequences which terminate transcription or translation. Expression vectors usually include replication origins from which the vectors replicate independently of host  
30 cells.

The vector of the present invention includes DNA encoding the protein of the present invention. This DNA may be under the regulation of a viral promoter, and it may encode a selective marker. The present invention  
35 also encompasses the use of expression vectors capable of expressing DNA encoding the protein of the present invention in prokaryotic or eukaryotic hosts. The vector

is one which is compatible with the host, and the DNA encoding the protein of the present invention is inserted into the vector to allow its expression in the host containing the vector.

5           Expression vectors are generally designed for stable expression in their host cells, or for maximum amplification of the number of copies of the desired gene per cell. However, constant propagation of the expression vector in the host cell is not necessarily  
10           required. A vector containing no replication origin recognized by the host cell may be used for temporary expression of the protein of the invention in a variety of host cells. There may also be used vectors which incorporate DNA encoding the protein of the invention  
15           into the DNA of the host by recombination.

          Such vectors include plasmids, viruses, bacteriophages, DNA fragments capable of being incorporated, and other vehicles capable of incorporating the DNA into the genome of the host. An expression  
20           vector is a specialized vector containing a genetic regulatory sequence which expresses a functionally linked gene. Plasmids are the most widely used form of vector, but vectors in various other forms which provide the same function and are known or will be known to those skilled  
25           in the art may also be suitably used according to the present specification.

          Suitable hosts are, as mentioned above, prokaryotic organisms, lower eukaryotic organisms and yeast, and higher eukaryotic organisms. Prokaryotic organisms  
30           include gram-negative and gram-positive organisms, such as *E. coli* and *B. subtilis*. Lower eukaryotic organisms include yeasts such as *S. cerevisiae* and species of *Pichia* and *Dictyostelium*. Higher eukaryotic organisms include cultured tissue cell systems established from  
35           animals cells from both non-mammalian sources, such as insect cells and mammalian sources such as humans, primates and rodents.

Prokaryotic host-vector systems include a wide range of vectors for many diverse species. The terms "*E. coli*" and "its vector" in the present specification will be used in an inclusive sense to encompass equivalent  
5 vectors for other prokaryotic organisms. A representative vector for amplifying DNA is pBR322 or any desired derivative thereof. Vectors used to express the calcium-binding proteins or fragments thereof include, but are not limited to, those comprising lac promoter  
10 (pUC series), those comprising trp promoter (pBR322-trp), those comprising Ipp promoter (pIN series), those comprising  $\gamma$ -pP or pR promoter (pOTS) and those comprising the ptac hybrid promoter (pDR540).

For reference, see Brosius, et al., "Expression  
15 Vector Employing Lambda-, trp-, lac-, and Ipp-derived Promoters", Vectors: A Survey of Molecular Cloning Vectors and Their Uses (ed. by Raymond L. Rodriguez and David T. Denhardt), Butterworth, Boston, 1988, Chap.10, 205-236.

20 Lower eukaryotic organisms such as yeast and *Dictyostelium* may be transformed using a vector containing a sequence encoding the protein of the present invention. Many other strains and species may be used for the purpose of the present invention, but the most  
25 widely used lower eukaryotic host is the baker's yeast *Saccharomyces cerevisiae*, which will be used to comprehensively represent lower eukaryotic organisms. The yeast vector comprises a replication origin (provided it is not an incorporating type), a selection gene, a  
30 promoter, DNA encoding the protein of the invention, and sequences for translation termination, polyadenylation and transcription termination.

Suitable yeast expression vectors include  
35 constitutive promoters such as 3-phosphoglycerate kinase and various other glycolytic enzyme gene promoters or inductive promoters such as alcohol dehydrogenase 2 promoter or metallothionein promoter. Suitable vectors



also include the following types of derivatives:  
autoreplicating low-copy types (e.g. YRp series),  
incorporating types (e.g. YIp series) and minichromosome  
types (e.g. YCp series).

5           Cultured tissue cells of higher eukaryotic organisms  
are the preferred type of host cells for expression of  
the functionally active calcium-binding protein.  
Theoretically, any system of cultured eukaryotic tissue  
10           cells may be used even if the source is an invertebrate  
animal. Mammalian cells, however, are preferred. The  
transformation or transfection and growth of such cells  
are carried out by routine techniques. Examples of  
useful cell systems are HeLa cells, Chinese hamster ovary  
(CHO) cell systems, baby rat kidney (BRK) cell systems,  
15           insect cell systems, and simian (COS) cell systems.

          Expression vectors for such types of cell systems  
usually comprise a replication origin, a promoter, a  
ribosome-binding site, an RNA-splicing site (when genomic  
DNA is used), a polyadenylation site and a transcription  
20           termination site. These vectors usually also include a  
selection gene or amplification gene. Suitable  
expression vectors include plasmids, viruses and  
retroviruses carrying promoters derived from sources such  
as adenovirus, SV40, parvovirus, vaccinia virus and  
25           cytomegalovirus. Representative of such suitable  
expression vectors are pCDNA1, pCD (Okayama, et al., Mol.  
Cell Biol. 5: 1136 - 1142, 1985), pMC1neo Poly A  
(Thomas, et al., Cell 51: 503 - 512, 1987) and  
baculovirus vectors such as pAC373 and pAC610.

30           The present invention also provides cells  
transformed by a vector containing DNA encoding the  
calcium-binding protein or fragments thereof.

          The transformed cells are cells which have been  
transformed or transfected with an expression vector for  
35           the calcium-binding protein prepared using a recombinant  
DNA technique. The transformed host cells express the  
calcium-binding protein or fragment thereof, but if the

purpose is cloning, amplification or manipulation of the DNA, expression of the calcium-binding protein is not necessary.

5 The protein of the invention and DNA encoding it have a variety of uses. That is, the DNA may be used for production of the protein it encodes, and it is also particularly useful for detection and identification of genes coding for related or homologous calcium-binding proteins, genes coding for subtypes of the calcium-  
10 binding protein, and genes coding for the calcium-binding proteins of different species.

The present invention further relates to uses of the calcium-binding protein, fragments and peptides thereof, and fusion products of these, in various assay systems  
15 and diagnostic agents for detecting the presence of and quantifying the calcium-binding protein.

The calcium-binding proteins of the invention and fragments thereof may also be employed as standard substances in the above-mentioned assay systems.

20 The calcium-binding proteins of the invention and fragments thereof may also be used as immunogens for making antiserum or antibodies specific to the calcium-binding protein or fragments thereof. The purified calcium-binding protein may be used to screen monoclonal  
25 antibodies obtained by immunization with a low purity preparation of the calcium-binding protein. The calcium-binding protein may also be used as an immunogen for producing the antibody of the present invention.

30 The present invention further provides antibodies with affinity to the calcium-binding protein. The present invention relates to, for example, antibodies with affinity to or produced against the calcium-binding protein with the amino acid sequence listed as in  
35 SEQ ID NO: 1 or 12, and fragments of the antibody. The antibodies may be produced against either the native or the recombinant form of the calcium-binding protein.

Antibodies against a fragment of the calcium-binding

protein of the invention may be produced by immunizing an animal with a conjugate of an immunogenic protein and the fragment. A monoclonal antibody may be prepared from cells secreting the desired antibodies. These antibodies  
5 may be screened by their binding with the calcium-binding protein.

The calcium-binding protein of the invention or fragment thereof may be fused or covalently conjugated to a polypeptide to be used as an immunogen for  
10 immunization. The calcium-binding protein or fragment thereof may also be fused or covalently conjugated to various common immunogens, for example, keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, and the like, for immunization. The animal to be immunized may  
15 be a cow, horse, goat, sheep, rabbit, chicken, guinea pig, rat, mouse, etc. and there are no restrictions provided the desired antibody can be obtained from the animal upon immunization.

For explanations regarding methods for preparing polyclonal antiserum, refer to, for example,  
20 Microbiology, Hoeber Medical Division (Harper and Row, 1969), Landsteiner, Specificity of Serological Reactions (Dover Publications, New York, 1962) and Williams, et al., Methods in Immunology and Immunochemistry, Vol.1  
25 (Academic Press, New York, 1967) (These are all incorporated in the present specification by reference). A typical method involves booster immunization of an animal with the antigen.

Polyclonal antibodies according to the present  
30 invention may be obtained according to a common method, by periodically immunizing an animal such as a horse, goat, sheep, rabbit, chicken or guinea pig with the above-mentioned antigen peptide either alone or mixed with an adjuvant. Blood, eggs, etc. may be taken from  
35 the animal which has been immunized preferably 3 times or more, and the polyclonal antibodies recovered.

The present invention further provides monoclonal

antibodies with binding affinity to the calcium-binding protein. The present invention still further provides hybridomas which produce the above-mentioned monoclonal antibodies.

5           In many cases, it is desirable for monoclonal antibodies to be prepared from a mammalian host, for example a rodent such as a mice or rat, a primate, human, etc. Explanations of a technique for preparing such monoclonal antibodies may be found in Stites, et al.,  
10   Basic and Clinical Immunology, (Lang Medical Publications, Los Altos, CA, 4th edition) and references therein, and particularly in Kohler and Milstein, Nature 256: 495 - 497 (1975) (discussing one method of producing monoclonal antibodies).

15           To briefly summarize, mice, rats, etc. are periodically immunized with the above-mentioned antigen either alone or in admixture with an adjuvant. Preferably after three or more immunizations, the spleen or lymph nodes are extracted and the B cells are fused  
20   with suitable myeloma cells. The fused cell lines are "hybridomas" which may be cultured *in vitro*. The resultant hybridoma cells are cultured in an appropriate culture solution such as HAT-RPMI1640 medium containing 10% fetal calf serum.

25           The antibodies produced in the culture supernatants are detected by, for example, RIA or ELISA, and the hybridoma cell lines producing antibodies which react specifically with the calcium-binding protein are selected and cloned. Each of the clones secretes one  
30   type of antibody against the immunogen. Each individual antibody type obtained is the product of a single B cell from the immunized animal, produced in response to a specific site (epitope) recognized on the immunogenic substance.

35           Monoclonal antibodies reacting with the calcium-binding protein of the invention may be recovered from ascites fluid obtained after transplanting hybridoma

cells into the peritoneal of mice or rats, for example. They may also be recovered from a culture supernatant of the hybridoma cells.

5 The recovered monoclonal or polyclonal antibodies may be separated and purified by a publicly known method such as ammonium sulfate precipitation or chromatography.

10 The antibodies of the invention may be used for affinity chromatography. The affinity chromatography may be used to purify the calcium-binding protein of the invention. A column is prepared with an antibody bound to a solid carrier, such as particles of agarose, sepharose or a similar substance, a sample containing the calcium-binding protein is passed through the column, the column is washed, and then a weak denaturant is flowed  
15 through to elute out the purified calcium-binding protein.

20 The present invention further provides detection methods and assay methods for the calcium-binding protein and fragments thereof, which methods employ the above-mentioned antibodies.

25 The detection systems and assay systems for the calcium-binding protein may be either homogeneous (not including a stage of separating the free reagent and the calcium-binding protein-antibody complex) or heterogeneous (including the separating stage).

30 The detection system and assay system for the calcium-binding protein of the present invention typically comprises a labelled antibody with binding affinity to the calcium-binding protein, a source of the calcium-binding protein (native or recombinant) and means for separating the conjugate from the free labelled compound, for example a solid-phase antibody with binding affinity to the calcium-binding protein for  
35 immobilization of the calcium-binding protein.

In these assay systems, the antibody or the calcium-binding protein and fragments thereof may be directly or indirectly labelled by covalent or non-covalent bonding

to obtain a direct or indirect detectable signal. Direct labelling methods include radioactive labelling, such as with  $^{125}\text{I}$ , enzymes (USP No. 3,645,090), e.g. peroxidase and alkaline phosphatase, and fluorescent labelling (USP  
5 No. 3,940,475). This also includes biotinylation and binding to biotin of avidin or streptoavidin labelled with one of the aforementioned labelling groups. An unlabelled antibody may be used by employing a labelled second antibody which recognizes that antibody.

10 Using an obtained antibody against the calcium-binding protein, and constructing a publicly known immunoassay system based on radioimmunoassay (RIA), enzyme immunoassay (EIA) or fluorescent immunoassay (FIA), it is possible to detect and measure the calcium-  
15 binding protein or fragments thereof.

One example of a known immunoassay method that may be applied is the so-called competitive immunoassay. For example, a prescribed amount of the calcium-binding  
20 protein which has been labelled with a radioactive isotope or the like is mixed with a specimen, and the anti-calcium-binding protein antibody is mixed therewith and allowed to react with the calcium-binding protein in the specimen and the labelled calcium-binding protein.

Since the calcium-binding protein in the specimen  
25 competes with the labelled calcium-binding protein to react with the anti-calcium-binding protein antibody, the reaction with the labelled calcium-binding protein decreases in proportion to the calcium-binding protein present in the specimen. After the reaction, the anti-  
30 calcium-binding protein antibody is either first bound to a solid-phase carrier, or anti-Ig antibody, protein A are reacted to the anti-calcium-binding protein antibody to separate the bound and unbound labelled calcium-binding protein. The non-binding fraction is removed by a  
35 commonly used method, and the bound radioactive isotope or other labelling is detected to allow measurement of

the calcium-binding protein.

Another example of a publicly known immunoassay method which may be applied is the so-called double antibody sandwich system. For example, the anti-calcium-binding protein antibody is bound to a solid-phase carrier commonly employed in immunoassay methods, such as a microtiter plate, beads, nitrocellulose membrane, nylon membrane, etc. and it is contacted with a specimen to react the calcium-binding protein in the specimen with the anti-calcium-binding protein antibody on the solid-phase carrier. The non-binding fraction is washed out by a common method and the anti-calcium-binding protein antibody which has been labelled with a radioactive isotope, enzyme, fluorescent substance, biotin or the like, is contacted with the calcium-binding protein bound to the anti-calcium-binding protein antibody on the carrier for reaction therewith.

The non-binding fraction is washed out by a commonly used method, and the labelled radioactive isotope, enzyme, fluorescent substance or biotin is detected to allow measurement of the calcium-binding protein. The anti-calcium-binding protein antibody and labelled anti-calcium-binding protein antibody used in this assay system may be monoclonal antibodies, polyclonal antibodies or a combination thereof. What is essential here is proper combinations of antibodies to allow the carrier-bound antibody/calcium-binding protein complex to bind to the labelled antibody, and such antibody combinations may be selected to suit the construction of any of the above-mentioned systems.

The calcium-binding proteins or fragments thereof in tissue may also be detected by immunohistological staining, which also reveals the local morphology of tissues or cells. Examples of antibody labelling using immunohistological staining include fluorescent pigments and enzymes for light microscopy and ferritin and gold colloids for electron microscopy. The immunohistological

staining is typically performed by, for example, fixing tissue slices or cells with an appropriate fixing agent such as alcohol, acetone, paraformaldehyde, etc. and reacting the anti-calcium-binding protein antibody therewith. After washing, detection of the labelling is made directly in the case of direct labelling, after further reaction with a labelled moiety and washing in the case of indirect labelling, by fluorescent microscope in the case of fluorescent labelling, by light microscope after reaction with a suitable substrate in the case of enzyme labelling, and by electron microscope in the case of metal particle labelling.

These immunoassay methods have been thoroughly discussed in literature.

An antibody of the present invention is also useful for diagnosis.

From the results obtained by the immunohistological staining and immunoassay described above, it is possible to determine the tissue and cellular distribution of the calcium-binding protein. This will yield information on the physiological role of the calcium-binding protein and elucidate its connection with various diseases. Its connection with diseases will provide clues for its utility as a diagnostic agent for those diseases.

For example, an antigen specifically present in cancerous cells may be useful as a marker for tumor diagnosis. Also, antigens abundantly present in cell groups involved in inflammation, such as neutrophils, leak out into the blood as inflammation progresses, and thus their blood concentrations may be useful as markers for diagnosis of inflammation. Furthermore, antigens which are abnormally expressed in connection with skin diseases may be used as markers for those diseases.

Thus, assay systems for the above-mentioned calcium-binding protein or fragments thereof may be used in diagnostic agents to yield useful information as an inflammatory disease marker, a neoplastic disease



(especially epidermoid carcinoma of the skin, esophagus, respiratory tract, cervix, etc.) marker, a skin disease marker or a blood disease marker, for screening of patients during examinations, specifying the nature of diseases, monitoring the effects of treatment, etc.

Specimens to be assayed include patient blood, saliva and other body fluids, urine, feces and other excrement, extracted tissue, cells, and the like.

#### EXAMPLES

The present invention will now be explained in more concrete terms by way of the following examples.

##### Example 1: Detection of CAAF1

CAAF1 was detected by the following method. A sample was subjected to Tricine-SDS-PAGE according to the method described in Analytical Biochemistry 166, 368 - 379 (1987), in the presence and in the absence of 2-mercaptoethanol.

The gel was silver-stained with a Silver Stain Kit Wako (Wako Pure Chemical Industries) to detect the protein. Using amniotic fluid from cows in the 4th month of pregnancy as samples gave bands of many other proteins, as well as a band located at about 7 KDa corresponding to the CAAF1 calcium-binding protein in the bovine amniotic fluid (Fig. 3).

The calcium-binding protein was also detected by  $^{45}\text{Ca}$  overlay autoradiography as described below. The protein in the gel which had been subjected to Tricine-SDS-PAGE was transferred (by electroblotting) to an Immobilon-P (Millipore) membrane by the semidry method. The transfer membrane was shaken for 15 minutes in an overlay buffer (60 mM KCl, 5 mM  $\text{MgCl}_2$ , 10 mM imidazole-HCl, pH 6.8) three times, and then shaken at 37°C for 30 minutes in an overlay buffer containing 3.7 MBq/l  $^{45}\text{Ca}^{2+}$  to bind the  $^{45}\text{Ca}^{2+}$ . Washing for 10 minutes with the overlay buffer was repeated 3 times, and then after an additional 10 minutes of shaking in 50% ethanol, the transfer membrane

was dried and autoradiography was performed. Amniotic fluid from cows in the 4th month of pregnancy gave a small number of other weak bands as well as a strong band of apparent molecular weight about 7KDa corresponding to CAAF1 (Fig. 3). This confirmed the presence of a large amount of the calcium-binding protein in the bovine amniotic fluid.

Example 2: Purification of CAAF1

Acetic acid was added to 3 liters of amniotic fluid from cows in the 4th month of pregnancy, to adjust the pH to 3.0. The resulting precipitate was removed by centrifugation for 40 minutes at 9000 x G, and the supernatant was filtered and subjected to cation exchange chromatography. The supernatant was then applied to a S-Sepharose fast flow column (Pharmacia) equilibrated with 1 M acetic acid, and the adsorbed protein was eluted out with an ammonium acetate concentration gradient. When each of the fractions was subjected to <sup>45</sup>Ca overlay autoradiography, CAAF1 was detected in a wide range of fractions from 0.5-1 M ammonium acetate (Fig. 4).

The CAAF1-containing fractions were collected, lyophilized, and reconstituted with 5 ml of 1 M acetic acid. The solution was gel filtrated by a 16/90 Sephadex-G75 fine column (Pharmacia) equilibrated with 1 M acetic acid. Each of the fractions was subjected to Tricine-SDS-PAGE followed by <sup>45</sup>Ca<sup>2+</sup> overlay autoradiography in the same manner and the CAAF1-containing fractions were then subjected twice to reverse phase chromatography. That is, they were applied to a column filled with TSK ODS-120T (Toso) equilibrated with 0.1% trifluoroacetic acid, and the adsorbed protein was eluted out with an acetonitrile concentration gradient. CAAF1 was eluted out near ca. 40% acetonitrile concentration. The target fraction was then applied to a column filled with TSK Phenyl-5PW (Toso) equilibrated with 0.1% trifluoroacetic acid, and the adsorbed protein

was eluted out with an acetonitrile concentration gradient. CAAF1 was eluted out near ca. 30% acetonitrile concentration.

5 Through a series of purification procedures there was obtained 150 µg of the calcium-binding protein CAAF1 substantially unitary, producing a single band of apparent molecular weight about 7 KDa upon silver staining after Tricine-SDS-PAGE (Fig. 5).

10 Upon estimation of the molecular weight of the protein by gel filtration using 16/60 Superdex 75 pg (Pharmacia), CAAF1 exhibited an elution peak at about 30 KDa (Fig. 6). This suggests that CAAF1 exists in solution as homotrimers or tetramers.

15 Example 3: Determination of CAAF1 amino acid sequence

The amino acid sequence of the purified CAAF1 was determined from the N-terminal to the 51st amino acid residue using a protein sequencer (Applied Biosystems, Model 1477A). The sequence was as follows:

20 Thr Lys Leu Glu Asp His Leu Glu Gly Ile Ile Asn Ile  
Phe His Gln Tyr Ser Val Arg Val Gly His Phe Asp Thr  
Leu Asn Lys Arg Glu Leu Lys Gln Leu Ile Thr Lys Glu  
Leu Pro Lys Thr Leu Gln Asn Thr Lys Asp Gln Pro  
(SEQ ID NO: 2)

25 A 5 µg portion of the CAAF1 was digested at 37°C overnight with lysylendopeptidase (EC 3.4.21.50, Wako Pure Chemical Industries ) or *S. aureus* V8 proteinase (endoproteinase Glu-C, EC 3.4.21.19, Boehringer Mannheim), and the respective decomposition products (L1,  
30 L2, L3 and V1, V2) were purified by reverse phase chromatography. The amino acid sequences were determined with a protein sequencer. The sequences of each of the fragments obtained with lysylendopeptidase were as follows:

35 L1: Ile Phe Gln Asp Leu Asp Ala Asp (SEQ ID NO: 3)

L2: Asp Gly Ala Val Ser Phe Glu Glu Phe Val Val Leu  
(SEQ ID NO: 4)

L3: Thr Ala His Ile Asp Ile His Lys Glu (SEQ ID NO: 5)

The sequences of each of the fragments obtained with V8 proteinase were as follows:

V1: Leu Pro Lys Thr Leu Gln Asn Thr Lys Asp Gln Pro Thr  
5 Ile Asp Lys Ile Phe Gln Asp Leu Asp Ala Asp Lys Asp  
Gly Ala Val Ser Phe (SEQ ID NO: 6)

V2: Glu Phe Val Val Leu Val Ser Arg Val Leu Lys Thr Ala  
His Ile Asp Ile His Lys Glu (SEQ ID NO: 7)

The entire amino acid sequence of CAAF1 was  
10 determined by comparing and joining the N-terminal and  
partial peptide amino acid sequences (Figs. 1 and 2,  
underlined portion). This sequence comprises the amino  
acid sequence listed as Sequence No.1 (Figs. 1 and 2)  
without the N-terminal methionine.

15 Example 4: Preparation of cDNA library from fetal  
calf esophageal tissue

RNA was extracted from 2.5 g of fetal calf  
esophageal tissue by the AGPC method, to obtain about 15  
mg of total RNA. An Oligotex-dT30 <Super> (Nihon Roche)  
20 was used to prepare Poly A RNA from this total RNA  
following the procedure recommended by the manufacturer,  
and about 150 µg of Poly A RNA was obtained.

cDNA was synthesized from 5 µg of this Poly A RNA by  
reverse transcription. The first strand of cDNA was  
25 synthesized using a TimeSaver cDNA Synthesis Kit  
(Pharmacia) with Oligo(dT)12-18 as the primer, following  
the procedure recommended by the manufacturer. An EcoRI  
adapter was attached to both ends of the synthesized  
cDNA.

30 EcoRI was added to 25 µl of the obtained cDNA  
solution for digestion, 4 µl (0.5 µg/µl) of  
dephosphorylated γgt11 (Lambda gt11/EcoRI/CIAP-treated:  
Stratagene) was added, a 1/20 volume of 3 M sodium  
acetate buffer solution (pH 5.2) and a 2.5-fold volume of  
35 ethanol were added, and the mixture was allowed to stand  
at -20°C for one hour to precipitate the DNA. After  
centrifugation with a refrigeratd microcentrifuge at

15,000 rpm, 4°C for 10 minutes, the supernatant was discarded and the pellet was collected.

5 In order to wash the DNA, 75% ethanol was added and after centrifugation at 15,000 rpm, 4°C for 3 minutes the supernatant was discarded and the pellet was air-dried. The DNA pellet was dissolved in 8 µl of sterilized distilled water, and 1 µl of a 10 × T4 DNA ligase buffer solution (300 mM Tris-HCl, pH 7.8, 100 mM MgCl<sub>2</sub>, 100 mM DTT, 10 mM ATP) and 1 µl of T4 DNA ligase (Pharmacia) 10 were added for a 3 hour ligation reaction at 16°C, to incorporate the cDNA into γgt11.

15 An *in vitro* packaging reaction was then conducted to prepare phage. The reaction was conducted from 4 µl of ligation reaction solution using a Gigapack II Gold Kit (Stratagene), following the procedure recommended by the manufacturer.

20 After completion of the reaction, the phage titer was measured. A portion of the packaging reaction solution was used to infect *E. coli* strain Y1090 which had been cultured in maltose-added NZY medium (10 g/l NZ amine, 5 g/l yeast extract, 5 g/l NaCl, 2 g/l MgSO<sub>4</sub>•7H<sub>2</sub>O) and resuspended in 10 mM MgSO<sub>4</sub> to OD<sub>600</sub>=1.0. As a result, the phage present in the packaging reaction solution was found to have an infectivity of 9.0 × 10<sup>6</sup> 25 pfu/ml.

#### Example 5: Construction of probe

30 cDNA was synthesized from 200 ng of the Poly A RNA separated from fetal calf esophageal tissue, using random hexamer and an RNA PCR Kit (Takara Shuzo) following the procedure recommended by the manufacturer.

This first strand cDNA was used to construct a probe by the polymerase chain reaction (PCR). The PCR primer was designed from the amino acid sequence of CAAF1, and the following degenerate primers P7S1 (sense primer: 35 corresponding to LEDHLEG) and P7A1 (antisense primer: corresponding to AHIDIHK) were synthesized:

P7S1: 5'TT(A/C/G/T)GA(A/G)GA(C/T)CA(C/T)(C/T)T(A/C/G/  
T)GA(A/G)GG-3' (SEQ ID NO: 8)

P7A1: 5'TT(A/G)TG(A/G/T)AT(A/G)TC(A/G/T)AT(A/G)TG  
(A/C/G/T)GC-3' (SEQ ID NO: 9)

5 One nmole of each of the primers from the first  
strand cDNA was used in a PCR reaction. The PCR reaction  
was conducted using a DNA Thermal Cycler (Perkin-  
Elmer/Cetus), with 30 cycles of reaction at 94°C for 1  
minute, 48°C for 2 minutes and 72°C for 2 minutes.

10 The amplified PCR product was subjected to  
electrophoresis in a 4% agarose gel (FMC Bioproducts:  
NuSieve GTG 3:1), and a DNA fragment anticipated to be  
263 bp was cut out of the gel. This DNA fragment was  
purified using a Gene Clean Kit (Bio 101), and recovered  
15 in 10 µl of TE solution (10 mM Tris-HCl (pH 7.5), 1 mM  
EDTA).

A ligation reaction was performed with 5 µl of the  
DNA fragment solution and 1 µl of pTZ18R vector  
(Pharmacia, 50 ng/µl) digested with the restriction  
20 endonuclease SmaI, using a DNA Ligation Kit (Takara  
Shuzo) according to the procedure recommended by the  
manufacturer, to incorporate the cDNA into the pTZ18R  
vector.

*E. coli* strain JM109 (Toyobo) was transformed with 5  
25 µl of this vector solution according to the method of  
Hanahan (DNA cloning: A practical approach (ed. D.M.  
Glover), vol.1, p.109-, IRC Press, (1985)). The cells  
were seeded onto L-amp plates containing X-gal, and the  
white colonies were selected out, thus selecting colonies  
30 which were ampicillin-resistant and lacking β-  
galactosidase.

The selected clones were cultured in a 2 × YT-amp  
medium (1.6% bacto-trypton, 1% yeast extract, 0.5% NaCl,  
100 µg/ml ampicillin), and a Magic Prep DNA Miniprep Kit  
35 (Promega) was used to prepare DNA according to the  
procedure recommended by the manufacturer. The prepared  
DNA was reacted with USB Sequenase version 2.0 (U.S.

Biochemicals) using M13M4 primer (Takara Shuzo) under the conditions recommended by the manufacturer. The reaction product was subjected to electrophoresis, and the nucleotide sequence of the DNA incorporated into the vector was determined to confirm that it contained the nucleotide sequence for CAAF1.

To 5  $\mu$ l (1  $\mu$ g/ $\mu$ l) of DNA of the obtained clones were added 2  $\mu$ l of a 10  $\times$  T buffer (330 mM Tris-acetate (pH 7.9), 100 mM magnesium acetate, 5 mM DTT, 660 mM potassium acetate), 2  $\mu$ l of 0.1% BSA, 1  $\mu$ l of SacI (10 U/ $\mu$ l: Takara Shuzo) and 1  $\mu$ l of XbaI (10 U/ $\mu$ l: Takara Shuzo), the solution was adjusted to 20  $\mu$ l with sterilized distilled water and reacted at 37°C for one hour, after which the DNA was cut. The entire reaction solution containing the DNA fragments was subjected to electrophoresis in a 4% agarose gel (FMC Bioproducts: NuSieve GTG 3:1), and an approximately 280 bp DNA fragment was cut out of the gel. This DNA fragment was purified using a Gene Clean Kit (Bio 101), and recovered in 10  $\mu$ l of TE solution (10 mM Tris-HCl (pH 7.5), 1 mM EDTA).

Template DNA consisting of 3  $\mu$ l (about 25 ng) of the DNA fragment solution was labelled with [ $\alpha$ - $^{32}$ P]dCTP (Amersham) using a Megaprime DNA labelling system (Amersham), following the procedure recommended by the manufacturer. After completion of the labelling, a Nick column (Pharmacia) was used to purify the labelled DNA, which was used as a  $^{32}$ P-labelled probe to isolate cDNA for CAAF1.

#### Example 6: Isolation of cDNA for CAAF1 and determination of its nucleotide sequence

The cDNA library prepared from fetal calf esophagus was used to infect *E. coli* Y1090 cells which were then seeded at  $1 \times 10^4$  plaques per 90 mm dish. Twenty of the 90 mm dishes were prepared, to form about  $2.0 \times 10^5$  plaques. The formed plaques were transferred to a

Hybond-N membrane (Amersham), the membrane was treated for 2 minutes with a solution containing 0.5 M NaOH and 0.5 M NaCl and for 5 minutes with a solution containing 0.5 M Tris-HCl (pH 7.5) and 0.5 M NaCl, and then washed thoroughly with 0.1 × SSC and 0.1 M ammonium acetate and air-dried on filter paper.

The membrane surface binding the plaque DNA was treated with UV to crosslink the DNA onto the membrane, and incubated at 42°C for 2 hours in a prehybridization solution (6 × SSC, 5 × Denhardt's solution, 20 mM Tris-HCl (pH 7.5), 50% formamide, 0.5% SDS, 100 µg/ml denatured salmon sperm DNA) for blocking. The prehybridization solution was discarded, and to a fresh prehybridization solution was added a <sup>32</sup>P-labelled probe denatured to single strands by rapid cooling after treatment at 96°C for 5 minutes, and the membrane was immersed therein and incubated at 42°C overnight for hybridization.

The membrane was washed with a solution containing 2 × SSC, 0.5% SDS at room temperature for 15 minutes and at 42°C for 15 minutes, then with a solution containing 0.5 × SSC, 0.1% SDS at 42°C for 15 minutes, and then with a solution of the same composition at 42°C for 15 minutes. This was placed in a cassette with exposure film, exposed at -80°C for 24 hours, and developed.

The plaques at the spot in which hybridized signals were detected were collected, plaques were formed in the same manner, and the plaques were isolated.

Thus were obtained 12 phage clones containing the target DNA fragment. Of these, the 3 phage clones λP7/32, λP7/34 and λP7/51 were used to infect *E. coli* Y1090, and high-titer phage solutions were obtained by the plate/lysate method.

A Lambda TRAPPLUS DNA Isolation Kit (CLONTEC) was used to purify about 10 µg of phage DNA from 10 ml of phage solution, following the procedure recommended by



the manufacturer.

The incorporated DNA was amplified from this phage DNA by the PCR using  $\lambda$ gt11 primers. The  $\lambda$ gt11 primer (forward) and  $\lambda$ gt11 primer (reverse) (Takara Shuzo) listed below were added in an amount of 1  $\mu$ l (1 nmole/ $\mu$ l) each to 1  $\mu$ l (1 ng/ $\mu$ l) of the phage DNA, and 10  $\mu$ l of a 10  $\times$  PCR buffer (100 mM Tris-HCl (pH 8.3), 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% gelatin), 10  $\mu$ l of 2 mM dNTP and 0.5  $\mu$ l of Taq DNA polymerase (5 U/ $\mu$ l: Takara Shuzo) were added with sterilized distilled water to make 100  $\mu$ l. The PCR reaction was conducted using a DNA Thermal Cycler (Perkin-Elmer/Cetus), with 30 cycles of reaction at 94°C for 1 minute, 55°C for 2 minutes and 72°C for 2 minutes.  $\lambda$ gt11 primer (forward): 5'-GGTGGCGACGACTCCTGGAGCCCG-3' (SEQ ID NO: 10)  $\lambda$ gt11 primer (reverse): 5'-TTGACACCAGACCAACTGGTAATG-3' (SEQ ID NO: 11)

The amplified PCR product was subjected to electrophoresis in a 4% agarose gel (FMC Bioproducts: NuSieve GTG 3:1), and DNA fragments derived from the phage clones  $\lambda$ P7/32,  $\lambda$ P7/34 and  $\lambda$ P7/51 (about 600 bp, 550 bp and 450 bp) were cut out of the gel. The DNA fragments were purified using a Gene Clean Kit (Bio 101), and recovered in 10  $\mu$ l of TE solution (10 mM Tris-HCl (pH 7.5), 1 mM EDTA). The DNA fragments were incorporated by a ligation reaction into the vector pTZ18R (Pharmacia) digested with the restriction endonuclease SmaI, using a DNA Ligation Kit (Takara Shuzo) according to the procedure recommended by the manufacturer.

*E. coli* strain JM109 (Toyobo) was transformed with 5  $\mu$ l of the vector solutions according to the method of Hanahan (DNA cloning: A practical approach (ed. D.M. Glover), vol.1, p.109-, IRC Press, (1985)). The cells were seeded onto L-amp plates containing X-gal, and the white colonies were selected out, thus selecting colonies which were ampicillin-resistant and lacking  $\beta$ -

galactosidase.

The selected colonies were cultured in a 2 × YT-amp medium (1.6% bacto-trypton, 1% yeast extract, 0.5% NaCl, 100 µg/ml ampicillin), and a Magic Prep DNA Miniprep Kit (Promega) was used to prepare DNA according to the procedure recommended by the manufacturer. The plasmid DNAs were named pTZ/BP7-32, pTZ/BP7-34 and pTZ/BP7-51, respectively.

A 5 µg portion of each plasmid DNA, pTZ/BP7-32, pTZ/BP7-34 and pTZ/BP7-51 was reacted by USB Sequenase version 2.0 (U.S. Biochemicals) using M13M4 primer and M13MRV primer (Takara Shuzo) according to the method recommended by the manufacturer. The reaction product was subjected to electrophoresis in an acrylamide gel for sequencing, to determine the nucleotide sequence.

The lengths of the nucleotide sequences of pTZ/BP7-32, pTZ/BP7-34 and pTZ/BP7-51 were 602 bp, 562 bp and 448 bp, respectively, and their overlapping portions matched. The entire nucleotide sequence of 429 bp determined from the overlapping portions is listed as Sequence No.1 and in Figs. 1, 2.

From this nucleotide sequence, the amino acid sequence of CAAF1 which is the primary translation product, i.e. the amino acid sequence before possible posttranslational modification, is deduced. This amino acid sequence minus the N-terminal methionine residue correspond to the amino acid sequence of the CAAF1 isolated from bovine amniotic fluid.

Example 7: Preparation of monoclonal antibodies with binding affinity to CAAF1

Female BALB/c mice were intraperitoneally immunized with 1-2 µg of the purified CAAF1 with Freund's complete adjuvant. The mice were then intraperitoneally immunized with 1 µg of CAAF1 with Freund's incomplete adjuvant twice at 3 week intervals thereafter. At one week after the final immunization, blood was taken from the caudal vein, and the blood antibody titers against CAAF1 were

estimated by RIA described below. The mice with the highest blood antibody titers were selected and intravenously injected with 1  $\mu$ g of CAAF1.

After 3 days, the spleens were extracted and the spleen cells were washed with RPMI1640 medium, and then mixed in a proportion of 5:1 with SP2/O Ag14 myeloma cells which had been washed in the same manner. The medium was removed by centrifugation, 1 ml of 50% polyethylene glycol was added to the cell pellet while stirring gently and RPMI1640 medium was added slowly for dilution, for cell fusion. After washing the cells, they were suspended in RPMI1640 medium containing 10% fetal calf serum and hypoxanthine/aminopterin/thymine (HAT), and dispensed into a 96-well microplate at 200  $\mu$ l/well.

After 10 days of culturing at 37°C in the presence of 5% CO<sub>2</sub> gas, the presence or absence of anti-CAAF1 antibodies in the culture supernatants was determined by RIA as described below. Hybridoma cells producing anti-CAAF1 antibodies were cloned by the limiting dilution method, and anti-CAAF1 antibody-producing hybridoma cell lines were established.

Of the monoclonal antibodies thus obtained, the 4 clones CAAF1-16-5, CAAF1-22-5, CAAF1-25-25 and CAAF1-31-5 were used in the following experiment.

The subtypes of the antibodies were determined with a mouse monoclonal antibody Isotyping Kit (Amersham). It was found as a result that CAAF1-16-5, CAAF1-22-5 and CAAF1-31-5 were IgG<sub>1</sub> and CAAF-1-25-25 was IgG<sub>2a</sub>.

The hybridoma cells were transplanted into the peritoneal of BALB/c mice at about 10<sup>7</sup> cells per mouse, and the ascites fluid produced after 1-2 weeks was collected.

The monoclonal antibodies in the ascites fluid were purified by affinity chromatography using a column with Protein A-Binding Sepharose (Pharmacia). The ascites fluid was diluted 3-fold with a buffer solution

containing 3 M NaCl and 1.5 M glycine-HCl (pH 8.9), and after filtration it was applied a column filled with Protein A-Sepharose CL-4B (Pharmacia) which had been equilibrated with the same buffer solution, to bind the antibodies. The monoclonal antibodies were eluted out by 0.1 M citrate buffer (pH 6.0) for the IgG<sub>1</sub> monoclonal antibodies and 0.1 M citrate buffer (pH 5.0) for the IgG<sub>2b</sub> monoclonal antibodies. The fractions contained the antibodies at a purity of about 90% or greater, as estimated by SDS-PAGE.

The antibodies with binding affinity to CAAF1 were detected by radioimmunoassay (RIA) using purified CAAF1. The RIA was performed in the following manner. Rabbit anti-mouse IgG antibody (Immunobiology Research Laboratory) diluted to 10 µg/ml with PBS was added to a 96-well microplate (Xenobind) at 50 µl/well for coating. After washing with PBS containing 0.05% Tween20 (T-PBS), blocking of the wells was effected with a solution containing 3% bovine serum albumin (BSA). After washing 3 times in the same manner, 50 µl of a sample such as mouse antiserum or hybridoma culture supernatant was added and reacted therewith for one hour at room temperature.

After washing 3 times, PBS containing about 5000 cpm of <sup>125</sup>I-labelled CAAF1 (<sup>125</sup>I-CAAF1) and 3% BSA was added to each well and reacted therewith for one hour at room temperature. After washing 4 times, the <sup>125</sup>I-CAAF1 binding to the antibodies from the sample was released with 10% acetic acid, and the radioactivity in the solution was measured with a gamma counter.

The <sup>125</sup>I-CAAF1 was prepared by reacting purified CAAF1 with [<sup>125</sup>I]-NaI using a Iodogen (Pierce), and separating the unreacted portion by gel filtration in a column filled with Sephadex-G25 (Pharmacia). This is the method described in the manual by Pierce Co.

Example 8: Detection of CAAF1 in tissue by immunohistological staining

In order to detect CAAF1 protein in fetal calf tissue and excised human tissue, the CAAF1 protein was immunohistochemically stained using a HISTOFINE immunohistochemical staining system (Nichirei). The fetal calf tissues listed in Tables 1 and 2, and excised human tissue, were fixed in a 15% formalin buffer solution and embedded in paraffin. After removing the slices from the paraffin, they were treated for 20 minutes with methanol containing 3% hydrogen peroxide to eliminate the intrinsic peroxidase activity.

After additional blocking with blocking reagent II (10% normal rabbit serum), CAAF1-22-5 hybridoma ascites fluid, diluted 1000-fold with PBS containing 3% BSA, was used as a primary antibody and reacted with each of the slices at room temperature for 2 hours. After 5-minute washing with PBS 3 times, they were reacted with a secondary antibody (biotin-labelled rabbit anti-mouse IgM + IgA + IgG antibody, 10 µg/ml) at room temperature for one hour. After 5-minute washing with PBS 3 times, they were further reacted with an enzyme reagent (peroxidase-labelled streptoavidin, 100 µg/ml) at room temperature for 30 minutes. After 5-minute washing with PBS 3 times, they were finally reacted with the peroxidase substrate diaminobentidine, and the presence of CAAF1 was visually determined.

Photographs showing the results are provided in Figs. 8 to 13. The presence or absence of reaction is indicated in Tables 1 and 2.

With fetal calves, expression of CAAF1 protein was confirmed in epithelial tissue such as esophagus, skin and cornea and in lymphatic tissue such as spleen and thymus. Of the epithelial tissue, all squamous epithelial cells except for basal cells were positive, and in the blood and lymphatic tissues, neutrophils and macrophages were positive.

Table 1 Reactivity of anti-CAAF1 antibody  
with various tissues

		<u>Immunoreactivity</u>	
5	Central nervous system		
	Cerebrum	-	
	Cerebellum	-	
	Brain stem	-	
10	Spinal cord	-	
	Cardiovascular system		
	Aorta	-	
	Vena cava	-	
15	Heart	-	
	Lymphatic tissue		
	Thymus	++	Hassall body, macrophage, PMN
20	Spleen	+++	Macrophage, PMN
	Digestive system		
	Parotid gland	-	
	Submaxilla	-	
25	Esophagus	+++	Epithelium/platocytes
	Stomach	-	
	Duodenum	-	
	Jejunum	-	
	Colon	-	
30	Liver	-	
	Pancreas	-	
	Respiratory system		
35	Trachea	+	Epithelium/ciliated and non-ciliated epithelial cells
	Lungs	-	

Table 2: Reactivity of anti-CAAF1 antibody  
with various tissues

		<u>Immunoreactivity</u>	
5	Urinary system		
	Kidneys	-	
	Urinary duct	-	
	Bladder	-	
10	Genitals		
	Gonads	-	
	Endocrine organs		
15	Pituitary gland	-	
	Adrenal gland	-	
	Skin		
20	Skin	+++	Cuticle/keratinous cells
	Sensory organs		
	Eye/cornea	+++	Epithelium/platycytes
	Eye/tunica conjunctiva	+++	Epithelium/platycytes
25	Other		
	Hematopoietic cells	+++	Macrophage, PMN
	Placenta	+++	Amniotic membrane/platycytes
30	Umbilical cord	+++	Amniotic membrane/platycytes
(PMN: Polymorphonuclear leukocytes)			
Of normal human tissue, CAAF1 protein			
35	immunoreactivity was confirmed and squamous epithelial		
	cells were positive in mucosal epithelial tissue such as		
	the esophagus and cervix. In the blood and lymphatic		
	tissue, the neutrophils and macrophages were positive.		
	However, of the normal human mucosal epithelial tissue		
	such as the esophagus and cervix in which CAAF1 protein		
40	immunoreactivity was confirmed, the atypical epithelial		
	cells were negative. Hyperexpression was confirmed in		
	cancerous areas of those tissues with a tendency to		
	cornification. Expression was also confirmed in		
	cancerous areas of lungs and skin in which no CAAF1		
45	protein immunoreactivity had been found when normal, and		
	hyperexpression was confirmed in those tissues with		
	pulmonary squamous-cell carcinoma with a strong tendency		

to cornification, squamous carcinoma of the skin, Bowen's disease (intraepithelial carcinoma) and senile keratosis (intraepithelial carcinoma). Furthermore, neutrophils and macrophages infiltrating the lesion sites exhibited strong CAAF1 protein immunoreactivity.

The existence of antigen reacting with CAAF1-22-5 monoclonal antibody in human tissue strongly suggests the existence in human tissue of a protein (human CAAF1) homologous with bovine CAAF1. Also, the differences of cancer cells and normal cells in immunoreactivities against the anti-CAAF1 antibody suggest the usefulness of the anti-CAAF1 antibody as a diagnostic agent for cancer (particularly squamous-cell carcinoma of the skin, oral cavity, esophagus, respiratory organs and cervix). In addition, the immunoreactivity of neutrophils and macrophages against anti-CAAF1 antibody further suggests additional usefulness of the anti-CAAF1 antibody as a diagnostic agent for various inflammatory diseases.

Example 9: Assay of CAAF1 in amniotic fluid and serum

The anti-CAAF1 monoclonal antibody CAAF1-22-5 was dissolved in a 50 mM sodium bicarbonate buffer at pH 9.6, to a concentration of 10 µg/ml. This solution was dispensed in an ELISA plate (NUNC) at 100 µl/well and incubated at 4°C overnight for coating of the monoclonal antibodies. After blocking with HBS (0.15 M NaCl, 20 mM HEPES-Na pH 7.4) containing 1% ovalbumin, a standard substance and the specimens were appropriately diluted with HBS containing 0.5% OVA and 0.05% Tween20 (OVA-T-HBS), and 100 µl thereof was added for reaction at room temperature for one hour.

After washing of the wells with HBS containing 0.05% Tween20 by a Plate Washer (Biotech), there was added 100 µl of OVA-T-HBS containing 1 µg/ml of biotin-labelled CAAF1-22-5 monoclonal antibody or biotin-labelled CAAF1-25-25 monoclonal antibody, for reaction at room temperature for one hour. After washing the wells,



100 µl of a horseradish peroxidase-labelled avidin D (vector) solution diluted 5000-fold with OVA-T-HBS was added thereto for reaction at room temperature for one hour. The wells were again washed, and then 100 µl of a solution containing o-phenylenediamine and hydrogen peroxide was added and a color development reaction was conducted at room temperature for 30 minutes. After stop of the reaction with 100 µl of 2 N sulfuric acid, stop the absorbance of each of the wells at 492 nm was measured with a microplate reader.

The above-mentioned biotin-labelled monoclonal antibodies were prepared in the following manner. A 2 mg portion of purified monoclonal antibody from each of the 4 clones, CAAF1-16-5, CAAF1-22-5, CAAF1-25-25 and CAAF1-31-5 was dissolved in 2 ml of 0.1 M borate buffer (pH 8.8), and after dialysis against the same buffer, 450 µg of NHS-LC-Biotin (Pierce) was added and allowed to react therewith at 4°C overnight. This was dialyzed against PBS, and the unreacted reagent was removed.

CAAF1 purified from bovine amniotic fluid was used as the standard substance, and the CAAF1 concentrations in the specimens were calculated from the calibration curve (Fig. 6).

With this assay system, it was possible to measure CAAF1 with a minimum detectable limit of about 10 pg/ml when using biotin-labelled CAAF1-25-25 monoclonal antibody and about 500 pg/ml when using biotin-labelled CAAF1-22-5 monoclonal antibody. Amniotic fluid from cows in the 4th month of pregnancy contained about 1 µg/ml of CAAF1 and bovine serum contained 20-60 ng/ml. No significant reaction was observed when biotin-labelled CAAF1-25-25 monoclonal antibody was used as opposed to a human specimen. When biotin-labelled CAAF1-22-5 monoclonal antibody was used, CAAF1 was measured at 20-200 ng/ml in normal human serum and at 2-5 ng/ml in human amniotic fluid.

These results demonstrate that the present invention

allows measurement of CAAF1 immunoreactivity in bovine and human body fluids. The fact that antigen reacting with CAAF1 22-5 monoclonal antibody was found to be present in human blood and amniotic fluid, strongly suggests the presence in human blood and amniotic fluid of a protein homologous with bovine CAAF1 (human CAAF1).

The results of the above-mentioned immunohistological staining which confirmed strong CAAF1 immunoreactivity of cancer cells (particularly squamous-cell carcinoma of the skin, esophagus, respiratory organs and cervix) as compared with normal cells, and the ability to measure CAAF1 immunoreactivity in human body fluids using anti-CAAF1 antibody, suggests the usefulness of this assay system for the diagnosis of cancer (particularly squamous-cell carcinoma of the skin, esophagus, respiratory organs and cervix). Also, the strong CAAF1 immunoreactivity of neutrophils and macrophages resulting from the above-mentioned immunohistological staining further suggests the usefulness of this CAAF1 assay system for the diagnosis of various inflammatory diseases.

Example 10: Construction of probe

From the DNA sequence of bovine CAAF1 was selected a sequence in the domain of the EF-hand motif believed to be highly conserved among species, and the following primers, BP7/242-261 (sense primer) and BP7/408-389 (antisense primer) were synthesized as PCR primers.

BP7/242-261: 5'-ATCATCAACATCTTCCACCA-3'

(SEQ ID NO: 13)

BP7/408-389: 5'-TCTTTATCGGCATCCAGGTC-3'

(SEQ ID NO: 14)

These primers were used for RT-PCR with an RNA PCR Kit (Takara Shuzo) from 50 ng of Poly A RNA extracted from human peripheral neutrophils and cultured human epidermal cells (Krabow) (cultured for 48 hours after addition of serum). After reverse transcription of the Poly A RNA, 3  $\mu$ l (10 pmole/ $\mu$ l) of each primer was added

to 10  $\mu$ l of cDNA solution, and 10  $\mu$ l of a 10  $\times$  PCR buffer (100 mM Tris-HCl (pH 8.3), 500 mM KCl, 15 mM MgCl<sub>2</sub>, 0.01% gelatin), 10  $\mu$ l of 2 mM dNTP and 0.5  $\mu$ l of Taq DNA polymerase (5 U/ $\mu$ l: Takara Shuzo) were added with  
5 sterilized distilled water to make 100  $\mu$ l. The PCR reaction was conducted using a DNA Thermal Cycler (Perkin-Elmer/Cetus), with 35 cycles of reaction at 94°C for 1 minute, 48°C for 2 minutes and 72°C for 2 minutes.

The anticipated PCR product of approximately 170 bp  
10 was amplified from all of the samples. After electrophoresis of the DNA fragments from human peripheral neutrophils with 4% agarose gel (FMC Bioproducts: NuSieve GTG3:1), they were purified using a Marmade Gene Clean Kit (Bio 101) and recovered in 10  $\mu$ l.  
15 of TE solution (10 mM Tris-HCl (pH 7.5), 1 mM EDTA).

A 5  $\mu$ l portion of each DNA fragment solution was ligated to pMOSBlue vector using a pMOSBlue T-vector Kit (Amersham), and *E. coli* strain JM109 (Toyobo) was transformed with 5  $\mu$ l of the vector solution according to  
20 the method of Hanahan (DNA cloning: A practical approach (ed. D.M. Glover), vol.1, p.109-, IRC Press, (1985)). The cells were seeded onto L-amp plates containing X-gal, and the white colonies were selected out, thus selecting colonies which were ampicillin-resistant and lacking  $\beta$ -galactosidase.  
25

The selected clones were cultured in a 2  $\times$  YT-amp medium (1.6% bacto-trypton, 1% yeast extract, 0.5% NaCl, 100  $\mu$ g/ml ampicillin), and a Wizard Prep DNA Miniprep Kit (Promega) was used to purify the plasmid DNA according to  
30 the procedure recommended by the manufacturer. The prepared DNA was reacted using an AutoRead Sequencing Kit (Pharmacia), under the conditions recommended by the manufacturer, and the nucleotide sequence was determined with an A.L.F.II DNA Sequencer (Pharmacia). The  
35 nucleotide sequence was confirmed to be about 80% homologous with the nucleotide sequence for bovine CAAF1.

In addition, the following primers, PMN.HP7S 1-15 and PMN.HP7A 126-112 were synthesized for the purpose of verifying the obtained nucleotide sequence, and an RT-PCR reaction was conducted from the above-mentioned Poly A  
5 RNA using an RNA PCR Kit (Takara Shuzo), with 35 cycles under reaction conditions of 94°C for 1 minute, 50°C for 1 minute and 72°C for 2 minutes.

PMN.HP7S 1-15: 5'-TACTCAGTTCGGAAG-3' (SEQ ID NO: 15)

PMN.HP7A 126-112: 5'-TTGGAATATTTTCATC-3'  
10 (SEQ ID NO: 16)

The anticipated PCR product of approximately 130 bp was amplified from all of the samples. After electrophoresis of the DNA fragments from human  
15 peripheral neutrophils with 4% agarose gel (FMC Bioproducts: NuSieve GTG3:1), they were purified using a Marmade Gene Clean Kit (Bio 101) and each DNA fragment was ligated to PCRII vector using a TA Cloning Kit (Invitrogen). *E. coli* strain JM109 (Toyobo) was  
20 transformed with 5 µl of the vector solution according to the method of Hanahan (DNA cloning: A practical approach (ed. D.M. Glover), vol.1, p.109-, IRC Press, (1985)), the cells were seeded onto L-amp plates containing X-gal, and the white colonies were selected out, thus selecting  
25 colonies which were ampicillin-resistant and lacking β-galactosidase.

A selected clone pHP7/PMN was cultured in a 2 × YT-amp medium (1.6% bacto-trypton, 1% yeast extract, 0.5% NaCl, 100 µg/ml ampicillin), and a Wizard Prep DNA  
30 Miniprep Kit (Promega) was used to purify the DNA according to the procedure recommended by the manufacturer. The prepared DNA was reacted using an AutoRead Sequencing Kit (Pharmacia), under the conditions recommended by the manufacturer, and the nucleotide  
35 sequence was determined with an A.L.F.II DNA Sequencer (Pharmacia). The nucleotide sequence was about 80% homologous with the nucleotide sequence for bovine CAAF1, and the overlapping portions matched exactly with the

nucleotide sequence mentioned above.

A 2 µg portion of DNA of the obtained clone pHP7/PMN was cut by one hour reaction at 37°C with EcoRI (20 U/µl: Takara Shuzo). All of the resulting DNA fragments were subjected to electrophoresis in a 4% agarose gel (FMC Bioproducts: NuSieve GTG3:1), and a DNA fragment of about 130 bp was cut out of the gel. This DNA fragment was purified using a Gene Clean Kit (Bio 101), and recovered in 10 µl of TE solution (10 mM Tris-HCl (pH 7.5), 1 mM EDTA).

Template DNA consisting of 3 µl (about 25 ng) of the DNA fragment solution was labelled with [ $\alpha$ -<sup>32</sup>P]dCTP (Amersham) using a Megaprime DNA labelling system (Amersham), following the procedure recommended by the manufacturer. After completion of the labelling, a Nick column (Pharmacia) was used to purify the labelled DNA, which was used as a <sup>32</sup>P-labelled probe to isolate cDNA for human CAAF1.

Example 11: Isolation of cDNA for human CAAF1 and determination of its nucleotide sequence

RNA was extracted from 0.5 g of adult human esophageal tissue using Isogen (Nippon Gene), to obtain about 1.5 mg of total RNA. An Oligotex-dT30 <Super> (Nihon Roche) was used to prepare Poly A RNA from this total RNA following the procedure recommended by the manufacturer, and about 50 µg of Poly A RNA was obtained.

cDNA was synthesized from 5 µg of this Poly A RNA using a TimeSaver cDNA Synthesis Kit (Pharmacia), according to the procedure recommended by the manufacturer. The primer used was NotI/Oligo(dT)18 primer (Directional Cloning Toolbox, Pharmacia). An EcoRI adapter was attached to both ends of the synthesized cDNA, and after phosphorylation and further addition of NotI for digestion, it was incorporated into dephosphorylated λExCell (λExCell NotI/EcoRI/CIP, Pharmacia).

An *in vitro* packaging reaction was then conducted using a Gigapack III Gold Kit (Stratagene), following the procedure recommended by the manufacturer. After completion of the reaction, a portion of the packaging reaction solution was used to infect *E. coli* strain NM522 which had been cultured in maltose-added NZY medium (10 g/l NZ amine, 5 g/l yeast extract, 5 g/l NaCl, 2 g/l MgSO<sub>4</sub>·7H<sub>2</sub>O) and resuspended in 10 mM MgSO<sub>4</sub> to OD600=2.0. As a result, the phage present in the packaging reaction solution was found to have an infectivity of  $1.0 \times 10^6$  pfu/ml.

A cDNA library prepared from adult human esophagus was used to infect *E. coli* NM522 cells which were then seeded at  $1 \times 10^4$  plaques per 90 mm dish. Twenty of the 90 mm dishes were prepared, to form about  $2.0 \times 10^5$  plaques. The formed plaques were transferred to a Hybond-N<sup>+</sup> membrane (Amersham), the membrane was treated for 2 minutes with a solution containing 0.5 M NaOH and 0.5 M NaCl and for 5 minutes with a solution containing 0.5 M Tris-HCl (pH 7.5) and 0.5 M NaCl, and then washed thoroughly with  $0.1 \times$  SSC and 0.1 M ammonium acetate and air-dried on filter paper.

The membrane surface binding the plaque DNA was treated with UV to crosslink the DNA onto the membrane. The membrane was incubated at 42°C for 2 hours in a prehybridization solution (6 × NET, 0.2 × Blotto, 50% formamide, 0.5% SDS, 200 µg/ml denatured salmon sperm DNA) for blocking. The prehybridization solution was discarded, and to a fresh prehybridization solution (5 × NET, 0.1 × Blotto, 30% formamide, 0.4% SDS, 10% dextran sulfate, 200 µg/ml denatured salmon sperm DNA) was added a <sup>32</sup>P-labelled probe denatured to single strands by rapid cooling after treatment at 96°C for 5 minutes, and the membrane was immersed therein and incubated at 42°C overnight for hybridization.

The membrane was washed with a solution containing

2 × SSC, 0.5% SDS at room temperature for 15 minutes,  
with a solution of the same composition at 50°C for 15  
minutes, then with a solution containing 0.5 × SSC, 0.1%  
SDS at 50°C for 15 minutes, and then with a solution of  
5 the same composition at 50°C for 15 minutes. This was  
placed in a cassette with exposure film, exposed at -80°C  
for 24 hours, and developed.

The plaques at the spot in which hybridized signals  
were detected were collected, plaques were formed in the  
10 same manner, and the plaques were isolated. Thus was  
obtained a single phage clone λExCell/HP7/ESO310  
containing the target DNA fragment.

The phage clone λExCell/HP7/ESO310 was used to  
infect *E. coli* NP66 to release phagmid pExCell/HP7/ESO310  
15 *in vivo* from λExCell/HP7/ESO310, and it was then  
separated and recovered using a Wizard Prep DNA Miniprep  
Kit (Promega). The purified pExCell/HP7/ESO310 was then  
infected into *E. coli* JM109 (Toyobo) to transform it.  
The cells were seeded onto L-amp plates containing X-gal,  
20 and the white colonies were selected out, thus selecting  
colonies which were ampicillin-resistant and lacking β-  
galactosidase.

The selected colonies were cultured together with  
helper phage VCSM-13 (Stratagene) in a 2 × YT-amp medium  
25 (1.6% bacto-trypton, 1% yeast extract, 0.5% NaCl, 100  
μg/ml ampicillin, 40 μg/ml kanamycin), and a Wizard M13  
DNA Miniprep Kit (Promega) was used to purify the single-  
stranded DNA according to the procedure recommended by  
the manufacturer.

30 A 2 μg portion of the single-stranded DNA of  
pExCell/HP7/ESO310 was reacted using an AutoRead  
Sequencing Kit (Pharmacia), under the conditions  
recommended by the manufacturer, and the nucleotide  
sequence was determined with an A.L.F.II DNA Sequencer  
35 (Pharmacia). The sequence was confirmed to be about 73%  
homologous with the nucleotide sequence for bovine CAAF1,  
and the overlapping portions matched exactly with the

nucleotide sequence of pHP7/PMN mentioned above.

In addition, the following primers were synthesized for the purpose of verifying the obtained nucleotide sequence, and an RT-PCR reaction was conducted from 100 ng of adult human esophageal Poly A RNA. The first strand cDNA was synthesized using a Ready-to-GO T-Primed First-Strand Kit (Pharmacia), following the procedure recommended by the manufacturer. The PCR was conducted with 35 cycles of reaction at 94°C for 1 minute, 60°C for 1 minute and 72°C for 1 minute.

HP7S 7-26: 5'-ACATTAGGCTGGGAAGATGA-3' (SEQ ID NO: 17)

HP7A 336-317: 5'-GGACATTGCTGGGTAAAAAG-3'  
(SEQ ID NO: 18)

As a result, the anticipated PCR product of approximately 330 bp was amplified, and after electrophoresis with a 4% agarose gel (FMC Bioproducts: NuSieve GTG3:1), the DNA fragment was purified and incorporated into a PCR Script vector (Stratagene) which had been digested with restriction endonuclease SmaI. *E. coli* JM109 (Toyobo) was transformed with this vector pHP7/ESO, and the cells were seeded onto L-amp plates containing X-gal and the white colonies were selected out, thus selecting colonies which were ampicillin-resistant and lacking  $\beta$ -galactosidase.

The selected clones were cultured together with helper phage VCSM-13 (Stratagene) in a 2 × YT-amp medium (1.6% bacto-trypton, 1% yeast extract, 0.5% NaCl, 100 µg/ml ampicillin, 40 µg/ml kanamycin), and a Wizard M13 DNA Miniprep Kit (Promega) was used to purify the single-stranded DNA according to the procedure recommended by the manufacturer.

A 2 µg portion of the single-stranded DNA of pHP7/ESO was reacted using an AutoRead Sequencing Kit (Pharmacia), under the conditions recommended by the manufacturer, and the nucleotide sequence was determined with an A.L.F.II DNA Sequencer (Pharmacia). The overlapping sequences matched exactly with the nucleotide



sequence of pExCell/HP7/ESO310 mentioned above.

Meanwhile, human neutrophil-derived Poly A RNA was used for RT-PCR in the same manner and the nucleotide sequence was determined, to confirm the nucleotide sequence of pExCell/HP7/ESO310.

The first strand cDNA was synthesized from 100 ng of adult human neutrophils using a TaKaRa RNA PCR Kit (Takara Shuzo), following the procedure recommended by the manufacturer. The PCR was conducted using the above-mentioned HP7S 7-26 and HP7A 336-317 as primers, with 35 cycles of reaction at 94°C for 1 minute, 58°C for 1 minute and 72°C for 2 minutes.

As a result, the anticipated PCR product of approximately 330 bp was amplified. A portion thereof was subjected to electrophoresis with a 4% agarose gel (FMC Bioproducts: NuSieve GTG Agarose), and the DNA fragment was recovered from the gel and purified. The DNA fragment was incorporated into a PCR II vector (Stratagene) using a TA Cloning Kit (Invitrogen) according to the procedure recommended by the manufacturer, and *E. coli* JM109 (Toyobo) was transformed with the vector. The cells were seeded onto an L-amp plate containing X-gal and the white colonies were selected out, thus selecting colonies which were ampicillin-resistant and lacking  $\beta$ -galactosidase.

The selected colonies were cultured in a 2 x YT-amp medium (1.6% bacto-trypton, 1% yeast extract, 0.5% NaCl, 100  $\mu$ g/ml ampicillin, 40  $\mu$ g/ml kanamycin), and a Wizard Minipreps DNA Purification System (Promega) was used to prepare DNA according to the procedure recommended by the manufacturer. This plasmid DNA was named pHP7/NEU.

A 10  $\mu$ g portion of the pHP7/NEU DNA was reacted using an AutoRead Sequencing Kit (Pharmacia), under the conditions recommended by the manufacturer, and the nucleotide sequence of the DNA incorporated into the vector was determined with an A.L.F.II DNA Sequencer (Pharmacia). The overlapping portions of the sequence

matched exactly with the nucleotide sequence of  
pExCell/HP7/ESO310 mentioned above.

5 RT-PCR was conducted in the same manner for human  
keratinocytes, and upon determining the nucleotide  
sequence of the amplified product, the overlapping  
portions thereof matched exactly with the nucleotide  
sequence of pExCell/HP7/ESO310.

The entire determined nucleotide sequence is shown  
in SEQ ID NO: 12.

10 From this nucleotide sequence, the amino acid  
sequence of human CAAF1 is deduced which is the primary  
translation product, i.e. the amino acid sequence before  
possible posttranslational modification.

11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000  
1001  
1002  
1003  
1004  
1005  
1006  
1007  
1008  
1009  
1010  
1011  
1012  
1013  
1014  
1015  
1016  
1017  
1018  
1019  
1020  
1021  
1022  
1023  
1024  
1025  
1026  
1027  
1028  
1029  
1030  
1031  
1032  
1033  
1034  
1035  
1036  
1037  
1038  
1039  
1040  
1041  
1042  
1043  
1044  
1045  
1046  
1047  
1048  
1049  
1050  
1051  
1052  
1053  
1054  
1055  
1056  
1057  
1058  
1059  
1060  
1061  
1062  
1063  
1064  
1065  
1066  
1067  
1068  
1069  
1070  
1071  
1072  
1073  
1074  
1075  
1076  
1077  
1078  
1079  
1080  
1081  
1082  
1083  
1084  
1085  
1086  
1087  
1088  
1089  
1090  
1091  
1092  
1093  
1094  
1095  
1096  
1097  
1098  
1099  
1100  
1101  
1102  
1103  
1104  
1105  
1106  
1107  
1108  
1109  
1110  
1111  
1112  
1113  
1114  
1115  
1116  
1117  
1118  
1119  
1120  
1121  
1122  
1123  
1124  
1125  
1126  
1127  
1128  
1129  
1130  
1131  
1132  
1133  
1134  
1135  
1136  
1137  
1138  
1139  
1140  
1141  
1142  
1143  
1144  
1145  
1146  
1147  
1148  
1149  
1150  
1151  
1152  
1153  
1154  
1155  
1156  
1157  
1158  
1159  
1160  
1161  
1162  
1163  
1164  
1165  
1166  
1167  
1168  
1169  
1170  
1171  
1172  
1173  
1174  
1175  
1176  
1177  
1178  
1179  
1180  
1181  
1182  
1183  
1184  
1185  
1186  
1187  
1188  
1189  
1190  
1191  
1192  
1193  
1194  
1195  
1196  
1197  
1198  
1199  
1200  
1201  
1202  
1203  
1204  
1205  
1206  
1207  
1208  
1209  
1210  
1211  
1212  
1213  
1214  
1215  
1216  
1217  
1218  
1219  
1220  
1221  
1222  
1223  
1224  
1225  
1226  
1227  
1228  
1229  
1230  
1231  
1232  
1233  
1234  
1235  
1236  
1237  
1238  
1239  
1240  
1241  
1242  
1243  
1244  
1245  
1246  
1247  
1248  
1249  
1250  
1251  
1252  
1253  
1254  
1255  
1256  
1257  
1258  
1259  
1260  
1261  
1262  
1263  
1264  
1265  
1266  
1267  
1268  
1269  
1270  
1271  
1272  
1273  
1274  
1275  
1276  
1277  
1278  
1279  
1280  
1281  
1282  
1283  
1284  
1285  
1286  
1287  
1288  
1289  
1290  
1291  
1292  
1293  
1294  
1295  
1296  
1297  
1298  
1299  
1300  
1301  
1302  
1303  
1304  
1305  
1306  
1307  
1308  
1309  
1310  
1311  
1312  
1313  
1314  
1315  
1316  
1317  
1318  
1319  
1320  
1321  
1322  
1323  
1324  
1325  
1326  
1327  
1328  
1329  
1330  
1331  
1332  
1333  
1334  
1335  
1336  
1337  
1338  
1339  
1340  
1341  
1342  
1343  
1344  
1345  
1346  
1347  
1348  
1349  
1350  
1351  
1352  
1353  
1354  
1355  
1356  
1357  
1358  
1359  
1360  
1361  
1362  
1363  
1364  
1365  
1366  
1367  
1368  
1369  
1370  
1371  
1372  
1373  
1374  
1375  
1376  
1377  
1378  
1379  
1380  
1381  
1382  
1383  
1384  
1385  
1386  
1387  
1388  
1389  
1390  
1391  
1392  
1393  
1394  
1395  
1396  
1397  
1398  
1399  
1400  
1401  
1402  
1403  
1404  
1405  
1406  
1407  
1408  
1409  
1410  
1411  
1412  
1413  
1414  
1415  
1416  
1417  
1418  
1419  
1420  
1421  
1422  
1423  
1424  
1425  
1426  
1427  
1428  
1429  
1430  
1431  
1432  
1433  
1434  
1435  
1436  
1437  
1438  
1439  
1440  
1441  
1442  
1443  
1444  
1445  
1446  
1447  
1448  
1449  
1450  
1451  
1452  
1453  
1454  
1455  
1456  
1457  
1458  
1459  
1460  
1461  
1462  
1463  
1464  
1465  
1466  
1467  
1468  
1469  
1470  
1471  
1472  
1473  
1474  
1475  
1476  
1477  
1478  
1479  
1480  
1481  
1482  
1483  
1484  
1485  
1486  
1487  
1488  
1489  
1490  
1491  
1492  
1493  
1494  
1495  
1496  
1497  
1498  
1499  
1500  
1501  
1502  
1503  
1504  
1505  
1506  
1507  
1508  
1509  
1510  
1511  
1512  
1513  
1514  
1515  
1516  
1517  
1518  
1519  
1520  
1521  
1522  
1523  
1524  
1525  
1526  
1527  
1528  
1529  
1530  
1531  
1532  
1533  
1534  
1535  
1536  
1537  
1538  
1539  
1540  
1541  
1542  
1543  
1544  
1545  
1546  
1547  
1548  
1549  
1550  
1551  
1552  
1553  
1554  
1555  
1556  
1557  
1558  
1559  
1560  
1561  
1562  
1563  
1564  
1565  
1566  
1567  
1568  
1569  
1570  
1571  
1572  
1573  
1574  
1575  
1576  
1577  
1578  
1579  
1580  
1581  
1582  
1583  
1584  
1585  
1586  
1587  
1588  
1589  
1590  
1591  
1592  
1593  
1594  
1595  
1596  
1597  
1598  
1599  
1600  
1601  
1602  
1603  
1604  
1605  
1606  
1607  
1608  
1609  
1610  
1611  
1612  
1613  
1614  
1615  
1616  
1617  
1618  
1619  
1620  
1621  
1622  
1623  
1624  
1625  
1626  
1627  
1628  
1629  
1630  
1631  
1632  
1633  
1634  
1635  
1636  
1637  
1638  
1639  
1640  
1641  
1642  
1643  
1644  
1645  
1646  
1647  
1648  
1649  
1650  
1651  
1652  
1653  
1654  
1655  
1656  
1657  
1658  
1659  
1660  
1661  
1662  
1663  
1664  
1665  
1666  
1667  
1668  
1669  
1670  
1671  
1672  
1673  
1674  
1675  
1676  
1677  
1678  
1679  
1680  
1681  
1682  
1683  
1684  
1685  
1686  
1687  
1688  
1689  
1690  
1691  
1692  
1693  
1694  
1695  
1696  
1697  
1698  
1699  
1700  
1701  
1702  
1703  
1704  
1705  
1706  
1707  
1708  
1709  
1710  
1711  
1712  
1713  
1714  
1715  
1716  
1717  
1718  
1719  
1720  
1721  
1722  
1723  
1724  
1725  
1726  
1727  
1728  
1729  
1730  
1731  
1732  
1733  
1734  
1735  
1736  
1737  
1738  
1739  
1740  
1741  
1742  
1743  
1744  
1745  
1746  
1747  
1748  
1749  
1750  
1751  
1752  
1753  
1754  
1755  
1756  
1757  
1758  
1759  
1760  
1761  
1762  
1763  
1764  
1765  
1766  
1767  
1768  
1769  
1770  
1771  
1772  
1773  
1774  
1775  
1776  
1777  
1778  
1779  
1780  
1781  
1782  
1783  
1784  
1785  
1786  
1787  
1788  
1789  
1790  
1791  
1792  
1793  
1794  
1795  
1796  
1797  
1798  
1799  
1800  
1801  
1802  
1803  
1804  
1805  
1806  
1807  
1808  
1809  
1810  
1811  
1812  
1813  
1814  
1815  
1816  
1817  
1818  
1819  
1820  
1821  
1822  
1823  
1824  
1825  
1826  
1827  
1828  
1829  
1830  
1831  
1832  
1833  
1834  
1835  
1836  
1837  
1838  
1839  
1840  
1841  
1842  
1843  
1844  
1845  
1846  
1847  
1848  
1849  
1850  
1851  
1852  
1853  
1854  
1855  
1856  
1857  
1858  
1859  
1860  
1861  
1862  
1863  
1864  
1865  
1866  
1867  
1868  
1869  
1870  
1871  
1872  
1873  
1874  
1875  
1876  
1877  
1878  
1879  
1880  
1881  
1882  
1883  
1884  
1885  
1886  
1887  
1888  
1889  
1890  
1891  
1892  
1893  
1894  
1895  
1896  
1897  
1898  
1899  
1900  
1901  
1902  
1903  
1904  
1905  
1906  
1907  
1908  
1909  
1910  
1911  
1912  
1913  
1914  
1915  
1916  
1917  
1918  
1919  
1920  
1921  
1922  
1923  
1924  
1925  
1926  
1927  
1928  
1929  
1930  
1931  
1932  
1933  
1934  
1935  
1936  
1937  
1938  
1939  
1940  
1941  
1942  
1943  
1944  
1945  
1946  
1947  
1948  
1949  
1950  
1951  
1952  
1953  
1954  
1955  
1956  
1957  
1958  
1959  
1960  
1961  
1962  
1963  
1964  
1965  
1966  
1967  
1968  
1969  
1970  
1971  
1972  
1973  
1974  
1975  
1976  
1977  
1978  
1979  
1980  
1981  
1982  
1983  
1984  
1985  
1986  
1987  
1988  
1989  
1990  
1991  
1992  
1993  
1994  
1995  
1996  
1997  
1998  
1999  
2000  
2001  
2002  
2003  
2004  
2005  
2006  
2007  
2008  
2009  
2010  
2011  
2012  
2013  
2014  
2015  
2016  
2017  
2018  
2019  
2020  
2021  
2022  
2023  
2024  
2025  
2026  
2027  
2028  
2029  
2030  
2031  
2032  
2033  
2034  
2035  
2036  
2037  
2038  
2039  
2040  
2041  
2042  
2043  
2044  
2045  
2046  
2047  
2048  
2049  
2050  
2051  
2052  
2053  
2054  
2055  
2056  
2057  
2058  
2059  
2060  
2061  
2062  
2063  
2064  
2065  
2066  
2067  
2068  
2069  
2070  
2071  
2072  
2073  
2074  
2075  
2076  
2077  
2078  
2079  
2080  
2081  
2082  
2083  
2084  
2085  
2086  
2087  
2088  
2089  
2090  
2091  
2092  
2093  
2094  
2095  
2096  
2097  
2098  
2099  
2100  
2101  
2102  
2103  
2104  
2105  
2106  
2107  
2108  
2109  
2110  
2111  
2112  
2113  
2114  
2115  
2116  
2117  
2118  
2119  
2120  
2121  
2122  
2123  
2124  
2125  
2126  
2127  
2128  
2129  
2130  
2131  
2132  
2133  
2134  
2135  
2136  
2137  
2138  
2139  
2140  
2141  
2142  
2143  
2144  
2145  
2146  
2147  
2148  
2149  
2150  
2151  
2152  
2153  
2154  
2155  
2156  
2157  
2158  
2159  
2160  
2161  
2162  
2163  
2164  
2165  
2166  
2167  
2168  
2169  
2170  
2171  
2172  
2173  
2174  
2175  
2176  
2177  
2178  
2179  
2180  
2181  
2182  
2183  
2184  
2185  
2186  
2187  
2188  
2189  
2190  
2191  
2192  
2193  
2194  
2195  
2196  
2197

SEQUENCE LISTING

SEQ ID NO: 1

SEQUENCE LENGTH: 429

SEQUENCE TYPE: nucleic acid

5 STRANDEDNESS: double

MOLECULE TYPE: cDNA

CHARACTERISTICS: Amino acid sequence of calcium-binding protein from bovine amniotic fluid and nucleotide sequence encoding it.

10 SEQUENCE:

	CTGGCATTCC	ACACTTCTGT	GCAGAGGGGT	GAACGTAGTT	TGGTAAA	ATG	ACT	53
						Met	Thr	
						1		
15	AAG CTG GAA GAT CAC CTG GAG GGA ATC ATC AAC ATC TTC CAC CAG TAC							101
	Lys Leu Glu Asp His Leu Glu Gly Ile Ile Asn Ile Phe His Gln Tyr							
	5		10		15			
	TCC GTT CGG GTG GGG CAT TTC GAC ACC CTC AAC AAG CGT GAG CTG AAG							149
	Ser Val Arg Val Gly His Phe Asp Thr Leu Asn Lys Arg Glu Leu Lys							
	20		25		30			
20	CAG CTG ATC ACA AAG GAA CTT CCC AAA ACC CTC CAG AAC ACC AAA GAT							197
	Gln Leu Ile Thr Lys Glu Leu Pro Lys Thr Leu Gln Asn Thr Lys Asp							
	35		40		45		50	
	CAA CCT ACC ATT GAC AAA ATA TTC CAA GAC CTG GAT GCC GAT AAA GAC							245
	Gln Pro Thr Ile Asp Lys Ile Phe Gln Asp Leu Asp Ala Asp Lys Asp							
25		55		60		65		
	GGA GCC GTC AGC TTT GAG GAA TTC GTA GTC CTG GTG TCC AGG GTG CTG							293
	Gly Ala Val Ser Phe Glu Glu Phe Val Val Leu Val Ser Arg Val Leu							
	70		75		80			
	AAA ACA GCC CAC ATA GAT ATC CAC AAA GAG TAGGAA GCTCTTTCCA							339
30	Lys Thr Ala His Ile Asp Ile His Lys Glu							
	85		90					
	GCAATGTCCC CAAGAAGACT TACCCCTTCTC CTCCCTGAGG CTGCCTTACC CGAGGGAAGA							399
	GAGAATTAAT AAACGTACTT TGGCAAAGTT							429

35 SEQ ID NO: 2

SEQUENCE LENGTH: 51

SEQUENCE TYPE: Amino acid

SEQUENCE:

40	Thr	Lys	Leu	Glu	Asp	His	Leu	Glu	Gly	Ile	Ile	Asn	Ile	Phe	His	Gln
	1						5					10				15

Tyr Ser Val Arg Val Gly His Phe Asp Thr Leu Asn Lys Arg Glu Leu  
20 25 30  
Lys Gln Leu Ile Thr Lys Glu Leu Pro Lys Thr Leu Gln Asn Thr Lys  
35 40 45  
5 Asp Gln Pro  
50

SEQ ID NO: 3  
SEQUENCE LENGTH: 8  
10 SEQUENCE TYPE: Amino acid  
SEQUENCE:  
Ile Phe Gln Asp Leu Asp Ala Asp  
1 5

15 SEQ ID NO: 4  
SEQUENCE LENGTH: 12  
SEQUENCE TYPE: Amino acid  
SEQUENCE:  
Asp Gly Ala Val Ser Phe Glu Glu Phe Val Val Leu  
20 1 5 10

SEQ ID NO: 5  
SEQUENCE LENGTH: 9  
SEQUENCE TYPE: Amino acid  
25 SEQUENCE:  
Thr Ala His Ile Asp Ile His Lys Glu  
1 5

SEQ ID NO: 6  
30 SEQUENCE LENGTH: 31  
SEQUENCE TYPE: Amino acid  
SEQUENCE:  
Leu Pro Lys Thr Leu Gln Asn Thr Lys Asp Gln Pro Thr Ile Asp Lys  
1 5 10 15  
35 Ile Phe Gln Asp Leu Asp Ala Asp Lys Asp Gly Ala Val Ser Phe  
20 25 30

SEQ ID NO: 7

**SEQUENCE:**

[illegible]

```

10      SEQUENCE LENGTH:  20
      SEQUENCE TYPE:  nucleic acid
      STRANDEDNESS:  single
      MOLECULE TYPE:  synthetic
      SEQUENCE:

```

```

SEQ ID NO: 9
SEQUENCE LENGTH: 20
SEQUENCE TYPE: nucleic acid
STRANDEDNESS: single
MOLECULE TYPE: synthetic
SEQUENCE:
TTRTGDATRT CDATRTGNGC

```

```

25      SEQ ID NO:   10
        SEQUENCE LENGTH:   24
        SEQUENCE TYPE:   nucleic acid
        STRANDEDNESS:   single
        MOLECULE TYPE:   synthetic
30      SEQUENCE:
        GGTGGCGACG ACTCCTGGAG CCCG

```

```

35  SEQ ID NO: 11
    SEQUENCE LENGTH: 24
    SEQUENCE TYPE: nucleic acid
    STRANDEDNESS: single
    MOLECULE TYPE: synthetic

```

SEQUENCE:

TTGACACCAG ACCAACTGGT AATG

SEQ ID NO: 12

5 SEQUENCE LENGTH: 441

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: double

MOLECULE TYPE: cDNA

10 CHARACTERISTICS: Nucleotide sequence of human calcium-binding protein and deduced amino acid sequence.

SEQUENCE:

GGTTAACATT AGGCTGGGAA G ATG ACA AAA CTT GAA GAG CAT CTG GAG GGA 51  
Mct Thr Lys Leu Glu Glu His Leu Glu Gly

15 ATT GTC AAT ATC TTC CAC CAA TAC TCA GTT CGG AAG GGG CAT TTT GAC 99  
Ile Val Asn Ile Phe His Gln Tyr Ser Val Arg Lys Gly His Phe Asp

ACC CTC TCT AAG GGT GAG CTG AAG CAG CTG CTT ACA AAG GAG CTT GCA 147  
Thr Leu Ser Lys Gly Glu Leu Lys Gln Leu Leu Thr Lys Glu Leu Ala

20 AAC ACC ATC AAG AAT ATC AAA GAT AAA GCT GTC ATT GAT GAA ATA TTC 195  
Asn Thr Ile Lys Asn Ile Lys Asp Lys Ala Val Ile Asp Glu Ile Phe

25 CAA GGC CTG GAT GCT AAT CAA GAT GAA CAG GTC GAC TTT CAA GAA TTC 243  
Gln Gly Leu Asp Ala Asn Gln Asp Glu Gln Val Asp Phe Gln Glu Phe

ATA TCC CTG GTA GCC ATT GCG CTG AAG GCT GCC CAT TAC CAC ACC CAC 291  
Ile Ser Leu Val Ala Ile Ala Leu Lys Ala Ala His Tyr His Thr His

30 AAA GAG TAGGTAGCTC TCTGAAGCT TTTTACCCAG CAATGTCCTC AATGAGGGTC 347  
Lys Glu

TTTTCTTTCC CTCACCAAAA CCCAGCCTTG CCCGTGGGGA GTAAGAGTTA ATAAACACAC 407  
TCACGAAAAG TTAAAAA AAAAATAA TTCT 441

35 SEQ ID NO: 13

SEQUENCE LENGTH: 20

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

MOLECULE TYPE: synthetic

40 SEQUENCE:

20

20

24

24

20

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single  
MOLECULE TYPE: synthetic  
SEQUENCE:  
GGACATTGCT GGGTAAAAAG

20

bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2014. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.